Historical Control Data on Histological Findings in 28 days Studies in RccHan™: WIST, Wistar Hannover Rats Recovery

Compiled from 28 days Bioassays performed at Harlan Laboratories Ltd. Itingen/Switzerland

Study Identification

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima-tization (days)	Body Weight: Delivery (g) M	Body Weight: Delivery (g) F	Housing	Diet	Vehicle	Pathologist
691896	1	☑	Juni-Juli 1998	Gavage	6	5	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	JMA
698894	2	☑	Juli-September 1998	Gavage	6	5	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	VOO
720707	3	☑	February-April 1999	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK
721440	4	☑	March-April 1999	Gavage	6	7	136 - 152	110 - 131	Group	Kliba 3433	Bi-distilled water	WEK
725567	5	☑	April-May 1999	Gavage	6	7	135 - 151	111 - 134	Group	Kliba 3433	Bi-distilled water	KHE
725264	6	☐	May-June 1999	Gavage	6	7	125 - 161	105 - 122	Group	Kliba 3433	Bi-distilled water	KHE
741835	7	☐	August-September 1999	Gavage	6	7	132- 179	104 - 134	Group	Kliba 3433	Bi-distilled water	KHE
737741	8	☐	August-September 1999	Gavage	6	7	122 - 158	102 - 127	Group	Kliba 3433	Bi-distilled water	KHE
693483	9	☑	May-July 1998	Gavage	6	7	135 - 172	108 - 143	Group	Kliba 3433	Bi-distilled water	KHE
706397	10	☑	September-November 1998	Gavage	6	7	129 - 176	122 - 147	Group	Kliba 3433	Bi-distilled water	KHE
706882	11	☑	October-Novemder 1998	Gavage	6	7	115 - 144	94 - 127	Group	Kliba 3433	Bi-distilled water	WEK
707591	12	☑	October-November 1998	Gavage	6	7	119 - 142	97 - 121	Group	Kliba 3433	Bi-distilled water	WEK
702033	13	☑	September-November 1998	Gavage	6	7	130 - 172	113 - 130	Group	Kliba 3433	Bi-distilled water	WEK
731305	14	☑	June-July 1999	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK
730023	15	☑	April-June 1999	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	KHE
746910	16	☐	October-November 1999	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK
724511	17	☐	May-June 1999	Gavage	6	7	139 - 161	107 - 131	Group	Kliba 3433	Polyethylene glycol (PEG) 300	KHE
716455	18	☑	February-April 1999	Gavage	6	7	124 - 136	116 - 125	Group	Kliba 3433	PEG 300	KHE
723082	19	☐	May-June 1999	Gavage	6	7	135 - 151	116 - 127	Group	Kliba 3433	PEG 300	WEK

Historical Control Data on Histological Findings in 28-days Studies in RccHan™: Wist, Wistar Hannover Rats, Recovery

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima-tization (days)	Body Weight: Delivery (g) M	Body Weight: Delivery (g) F	Housing	Diet	Vehicle	Pathologist
714306	20	☑	December 1998-February 1999	Gavage	6	7	135 - 156	117 - 132	Group	Kliba 3433	PEG 300	WEK
741508	21	☐	August-September 1999	Gavage	6	7	125 - 159	101 - 132	Group	Kliba 3433	PEG 300	KHE
727323	22	☑	April-June 1999	Gavage	6	7	113 - 145	104 - 131	Group	Kliba 3433	PEG 300	KHE
742252	23	☑	August-October 1999	Gavage	6	7	120 - 157	96 - 144	Group	Kliba 3433	PEG 300	WEK
747966	24	☐	December 1999-January 2000	Gavage	6	7	129 - 156	103 - 133	Group	Kliba 3433	PEG 300	KHE
747156	25	☐	November-December 1999	Gavage	6	7	149 - 185	122 - 145	Group	Kliba 3433	PEG 300	WEK
746730	26	☑	October-December 1999	Gavage	6	7	124 - 169	108 - 137	Group	Kliba 3433	PEG 300	WEK
744535	27	☐	November 1999-January 2000	Gavage	6	7	124 - 160	111 - 133	Group	Kliba 3433	PEG 300	WEK
727018	28	☐	April-May 1999	Gavage	6	7	134 - 147	115 - 128	Group	Kliba 3433	PEG 300	KHE
700075	29	☐	August-September 1998	Gavage	6	7	126 - 172	109 - 135	Group	Kliba 3433	PEG 300	WEK
720257	30	☐	February-March 1999	Gavage	6	7	137 - 150	112 - 124	Group	Kliba 3433	PEG 300	KHE
726074	31	☑	April-May 1999	Gavage	6	7	135 - 153	115 - 133	Group	Kliba 3433	PEG 300	WEK
710414	32	☐	January-February 1999	Gavage	6	7	179 - 196	118 - 129	Group	Kliba 3433	PEG 300	KHE
712135	33	☑	December 1998-January 1999	Gavage	6	7	140 - 157	111 - 132	Group	Kliba 3433	PEG 300	WIL
743512	34	☑	September-November 1999	Gavage	6	7	144 - 174	112 - 148	Group	Kliba 3433	PEG 300	MIP
648990	35	☑	February-April 1997	Gavage	6	7	127 - 165	109 - 145	Group	Kliba 343	Bi-distilled water	WIL
636456	36	☑	October-November 1996	Gavage	6	7	130 - 173	112 - 146	Group	Kliba 343	PEG 400	WEK
642240	37	☐	December 1996-January 1997	Gavage	6	7	132 - 173	127 - 145	Group	Kliba 343	Bi-distilled water	WIL
656572	38	☐	June-July 1997	Gavage	6	7	135 - 155	109 - 129	Group	Kliba 343	PEG 400	WIL
652601	39	☑	April-May 1997	Gavage	6	7	133 - 151	109 - 131	Group	Kliba 343	Bi-distilled water	WEK
637740	40	☑	November-December 1996	Gavage	6	7	127 - 172	110 - 146	Group	Kliba 343	Bi-distilled water	WEK

Historical Control Data on Histological Findings in 28-days Studies in RccHan^{TM}: Wist, Wistar Hannover Rats, Recovery

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima-tization (days)	Body Weight: Delivery (g) M	F	Housing	Diet	Vehicle	Pathologist
644365	41	☑	April-May 1997	Gavage	6	7	132 - 154	107 - 129	Group	Kliba 343	0.6 % Carboxymethylcellulose (CMC)	JMA
650744	42	☐	June-July 1997	Gavage	6	7	133 - 159	107 - 130	Group	Kliba 343	Sesame oil	WEK
643961	43	☑	March-April 1997	Gavage	4	14	118 - 140	87 - 109	Group	Kliba 343	Bi-distilled water	WIL
647651	44	☑	February-April 1997	Gavage	6	7	124 - 158	102 - 136	Group	Kliba 343	Bi-distilled water	WIL
660510	45	☐	July-August 1997	Gavage	6	7	127 - 157	110 - 133	Group	Kliba 343	Bi-distilled water	HJC
654917	46	☐	April-June 1997	Gavage	6	8	136 - 155	112 - 130	Group	Kliba 343	0.5 % CMC in Bi-distilled water	WEK
C29568	47	☑	February - March 2009	Inhalation	7 to 9	5	mean±20%	mean±20%	Group	Kliba 3433	Placebo	HJC
646154	48	☐	March-April 1997	Intravenous	7	7	171 - 197	133 - 154	Group	Kliba 343	Physiological saline (0.9% NaCl)	WIL
657505	49	☐	April-May 1997	Gavage	6	7	137 - 153	106 - 130	Group	Kliba 343	PEG 400	WEK
654287	50	☑	April-June 1997	Gavage	6	7	133 - 154	110 - 128	Group	Kliba 343	Bi-distilled water	WEK
653264	51	☑	April-June 1997	Gavage	6	6	132 - 155	109 - 129	Group	Kliba 343	Bi-distilled water	WEK
644253	52	☑	December 1996-February 1997	Gavage	6	7	135 - 176	103 - 143	Group	Kliba 343	Bi-distilled water	WIL
639731	53	☑	December 1996-January 1997	Gavage	6	7	127 - 176	98 - 130	Group	Kliba 343	Bi-distilled water	WIL
623777	54	☑	May-June 1996	Gavage	6	7	127 - 170	111 - 142	Group	Kliba 343	Bi-distilled water / PEG 400	WIL
617556	55	☑	February-April 1996	Gavage	6	7	149 - 173	120 - 148	Group	Kliba 343	Bi-distilled water	WIL
629234	56	☑	August-September 1996	Gavage	6	7	113 - 160	101 - 140	Group	Kliba 343	Bi-distilled water	WIL
632182	57	☑	August-October 1996	Gavage	6	7	125 - 181	98 - 129	Group	Kliba 343	Bi-distilled water	WIL
632722	58	☑	September-October 1996	Gavage	6	7	121 - 157	111 - 142	Group	Kliba 343	Corn oil	WIL
603527	59	☑	July-September 1995	Gavage	6	7	136 - 246	117 - 134	Individually	Kliba 343	Bi-distilled water	WIL
601378	60	☑	August-October 1995	Gavage	6	7	137 - 152	114 -126	Individually	Kliba 343	Bi-distilled water	WEK

Historical Control Data on Histological Findings in 28-days Studies in RccHan™: Wist, Wistar Hannover Rats, Recovery

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima-tization (days)	Body Weight: Delivery (g) M	F	Housing	Diet	Vehicle	Pathologist
B85318	61	☑	October - November 2008	Inhalation	♂:6-8♀:8-10	5	mean±20%	mean±20%	Groups	Kliba Nafag 3433	Formulation buffer of DA-3201	HJC
620662	62	☐	June-July 1996	Gavage	6	7	125 - 167	105 - 144	Groups	Kliba 343	Corn oil	WIL
C36476	63	☑	February - March 2009	Subcutaneous	6	7	150 (±20%)	125 (±20%)	Groups	Kliba Nafag 3433	4.5% Mannitol in water	PAV
609210	64	☐	January-March 1996	Gavage	6	7	136 - 160	119 - 137	Individually	Kliba 343	Bi-distilled water	WEK
618625	65	☑	April-May 1996	Gavage	6	7	150 - 176	106 - 127	Groups	Kliba 343	Corn oil	WEK
621551	66	☑	May-June 1996	Gavage	6	7	133 - 171	116 - 141	Groups	Kliba 343	Bi-distilled water	WEK
621821	67	☑	May-June 1996	Gavage	6	7	139 - 174	115 - 147	Groups	Kliba 343	PEG 400	WIL
643083	68	☑	December1996-January 1997	Gavage	6	7	126 - 172	99 - 145	Groups	Kliba 343	Bi-distilled water	WIL
846238	69	☐	October 2002 – November 2002	Gavage	6	7	134 - 158	111 - 130	Groups	Kliba 343	Corn oil	KOD
841496	70	☑	February 2002 – April 2002	Gavage	5	16	110 (±20%)	100 (±20%)	Groups	NAFAG 8900	Bi-distilled water	ABR
762658	71	☐	March – April 2000	Feeding	5	6	110 (±20%)	95 (±20%)	Groups	Kliba 3433	Diet	WEK
841039	72	☑	January – February 2002	Gavage	6	6	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	MIP
825467	73	☐	October – November 2002	Inhalation	♂:6-8♀:8-10	5	180 - 200	180 - 200	Groups	Kliba 3433	NaCl, 0.9% (0.9% w/v sodium chloride solution)	WEK
843046	74	☑	May – June 2002	Gavage	5	15	110 (±20%)	110 (±20%)	Groups	NAFAG 8900	0.5% CMC in 0.1% (w/v) aqueous polysorbate 80	ABR
842083	75	☑	April – May 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	NED
842083	76	☑	March – April 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	Bi-distilled water	NED
845763	77	☐	December 2002 - January 2003	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	Corn oil	WEK
844408	78	☐	July – August 2002	Gavage	6	5	No males	125 (±20%)	Groups	Kliba 3433	Group 01: CMC Group 02: Cremophor	KHE
849144	79	☐	Juni – Juli 2003	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	Ultrapure water	SPH
841855	80	☑	March – April 2002	Inhalation	♂ : 6 - 8 ♀ : 8 - 10	14	180-200	180-200	Groups	Kliba 3433	Air control	WEK
844400	81	☑	July – August 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Klba 3433	Hydroxyehtylcellulose zur Synthese 0,5%ig, Merck S22341743	JAG

Historical Control Data on Histological Findings in 28-days Studies in RccHan^{TM}: Wist, Wistar Hannover Rats, Recovery

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima-tization (days)	Body Weight: Delivery (g) M	Body Weight: Delivery (g) F	Housing	Diet	Vehicle	Pathologist
844782	82	☐	December 2002 - January 2003	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Klba 3433	PEG 300	NED
841798	83	☐	March - April 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Klba 3433	PEG 300	NED
830351	84	☑	January - February 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Klba 3433	PEG 300	TOX
829067	85	☑	October - November 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Klba 3433	0.5% Methocel MC	JAG
844804	86	☑	July - August 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Klba 3433	Methocel MC 0.25% in water	WEK
846939	87	☑	January - February 2003	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Klba 3433	Bi-distilled water	NED
841557	88	☑	February - March 2002	Gavage	6	6	150 (±20%)	125 (±20%)	Groups	Kliba 3433	Corn oil	PSC
820315	89	☐	July – August 2001	Gavage	12	7	220 (±20%)	250 (±20%)	Groups	Kliba 3433	4% Methocel E 15 with 2-3 drops of Med Antifoam C/200ml	WEK
843756	90	☑	July - August 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	Bi-distilled water	JAG
845279	91	☑	October - November 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	WEK
845307	92	☑	October - November 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	NED
843129	93	☑	March - April 2002	Intravenous	6	7	200 (±20%)	150 (±20%)	Individually	Kliba 3433	Group 01: PBS buffer Group 02: PC-Liposomes (B)	NED
845823	94	☑	October - November 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	KOD
845044	95	☑	September - Oktober 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	Bi-distilled water	GKR
841255	96	☐	February - March 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	GKR
844990	97	☐	August - September 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	0.5% aqueous solution of CMC	NED
844693	98	☐	August - September 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	1,2-propylene glycol	NED
842520	99	☑	March - April 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	GKR
842614	100	☑	April - May 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	NED
844256	101	☑	July - August 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	JAG
842658	102	☑	April - May 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	ABR

Historical Control Data on Histological Findings in 28-days Studies in RccHan^{TM}: Wist, Wistar Hannover Rats, Recovery

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima-tization (days)	Body Weight: Delivery (g) M	Body Weight: Delivery (g) F	Housing	Diet	Vehicle	Pathologist
841276	103	☑	January - February 2002	Gavage	6	7	125-158 (mean 142)	112-132 (mean 121)	Groups	Kliba 3433	PEG 300	NED
841901	104	☑	Feburary - March 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	HJC
845437	105	☑	November-December 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	KOD
844691	106	☐	August - September 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	Tylose CB 30000P2 (in 0.5% aqueous solution)	MIP
845375	107	☑	October - November 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	Bi-distilled water	AKR
841315	108	☐	January - February 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	Bi-distilled water	MIP
844692	109	☐	August - September 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	Bi-distilled water	MIP
841313	110	☑	January - February 2002	Gavage	6	5	150 (±20%)	125 (±20%)	Groups	Kliba 3433	Bi-distilled water	GKR
844149	111	☑	Juni – Juli 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	Bi-distilled water	MIP
843219	112	☑	May – June 2002	Gavage	5	13	110 (±20%)	100 (±20%)	Groups	Kliba 3433	CMC 0.5% (w/v)/ polysorbate (TWEEN) 80 0.1% (w/v)	ABR
826661	113	☑	January - February 2002	Inhalation	♂: 6 - 8 ♀: 8 - 10	14	180-200	180-200	Groups	Kliba 3433	Pharmatose 325 MESH 90%	WEK
843520	114	☑	July - August 2002	Gavage	6	7	150 (±20%)	125 (±20%)	Groups	Kliba 3433	PEG 300	GKR
842880	115	☑	April - May 2002	Gavage	8	7	230 (±20%)	170 (±20%)	Groups	Kliba 3433	Thixotrope	LAN
785103	116	☑	December 2000 - January 2001	Gavage	6	7	121 - 172	98 - 146	Groups	Kliba 3433	Bi-distilled water	WEK
814858	117	☐	May 2001 - June 2002	Dermal	6	7	91 - 128	89 - 118	Group	Kliba 3433	1% LAS 33774	WEK
832781	118	☐	October - December 2001	Gavage	6	7	119 - 155	108 - 132	Group	Kliba 3433	PEG 300	NED
783180	119	☐	September 2000 - August 2001	Dermal	♂: 9 ♀: 14	7	193 - 209	176 - 214	Group	Kliba 3433	FK117 GEL	WEK
793394	120	☑	November 2000 - Januar 2001	Gavage	6	7	126 - 160	111 - 172	Groups	Kliba 3433	Bi-distilled water	WEK
766405	121	☑	May- June 2000	Gavage	6	6	115 - 161	94 - 134	Group	Kliba 3433	Bi-distilled water	WEK
780118	122	☑	April- August 2001	Inhalation	♂: 6 - 8 ♀: 10 - 12	14	180 -	200	Group	Kliba 3433	DEXBUD/HFA	WEK
774270	123	☐	June - August 2000	Gavage	6	7	134 - 174	111 - 141	Group	Kliba 3433	Bi-distilled water	WEK

Historical Control Data on Histological Findings in 28-days Studies in RccHan™: Wist, Wistar Hannover Rats, Recovery

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima-tization (days)	Body Weight: Delivery (g) M	Body Weight: Delivery (g) F	Housing	Diet	Vehicle	Pathologist
707771	124	☑	January 1999-April 2001	Inhalation	♂ : 8 - 11 ♀ : 10-13	5 ; 14	179 - 241	179 - 211	Group	Kliba 3433	HFA	WEK
763582	125	☐	April - May 2000	Gavage	6	7	120 - 160	106 - 141	Group	Kliba 3433	Bi-distilled water	WEK
726557	126	☐	April - June 1999	Gavage	5	6	111 - 134	93 - 115	Group	Kliba 3433	LAS 32928	WEK
829067	127	☑	October 2002 - July 2003	Gavage	6	7	127 - 162	110 - 131	Group	Kliba 3433	0,5% aqueous Methocel solution	JAG
822510	128	☐	August - December 2001	Inhalation	♂ : 7 - 9 ♀ : 10 - 12	12	±20%	of the maen weight	Group	Kliba 3433	1 dose group: riboflavin formulation 3 dose group: AWD 12-281 formulation	WEK
789041	129	☐	June - August 2001	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Peanut oil (desiccated)	CMA
821316	130	☐	August - October 2001	Gavage	6	7	132 - 157	114 - 131	Group	Kliba 3433	PEG 300	KOD
B52323	131	☐	September- Novembre 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	PEG 300	BDK
B26201	132	☐	May- July 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	PEG 300	KHE
B10440	133	☑	March- April 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	PEG 300	BDK
851521	134	☑	April - May 2004	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	0,5% Methylcellulose	KHE
851858	135	☑	January - Febuary 2004	Gavage	6	6	150 (±20%)	125 (±20%)	Group	Kliba 3433	SSV	MAM
A92608	136	☑	September - October 2006	Gavage	7	7	175 (±20%)	140 (±20%)	Group	Kliba 3433	Aqua bidest	WEK
C16823	137	☐	December 2008 - January 2009	Intravenous	7	7-8	190(±20%)	150(±20%)	Group	Kliba 3433	PBS	KOD
852202	138	☑	Febuary - March 2004	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	WLA
852372	139	☑	February - March 2004	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	PAV
853022	140	☐	March - April 2004	Feeding	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Diet	WLA
855727	141	☑	January - March 2005	Intravenous	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	N1509 Injectable NanoCrystal	PAV
858100	142	☑	January - Febuary 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	NED
858304	143	☑	July - September 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	0.5% Carboxymethyl Cellulose	MAM
858351	144	☑	May - July 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Sterole water for injection	NED

Historical Control Data on Histological Findings in 28-days Studies in RccHan^{TM}: Wist, Wistar Hannover Rats, Recovery

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima-tization (days)	Body Weight: Delivery (g) M	Body Weight: Delivery (g) F	Housing	Diet	Vehicle	Pathologist
858417	145	☐	Febuary - March 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	JAG
858453	146	☑	April - June 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	NED
858591	147	☐	March - April 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	NED
858754	148	☑	March - May 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	VOO
858852	149	☑	March - April 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	NIH31-2050	0.5% Carboxymethyl Cellulose	NED
859022	150	☑	May - June 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	PAV
859141	151	☑	June - July 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3434	Corn Oil	ROL
859248	152	☑	March - April 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3434	Physiological saline (0.9% NaCl)	KHE
859361	153	☑	May - June 2005	Gavage	6	8	150 (±20%)	125 (±20%)	Group	Kliba 3434	PEG 300	ROL
A00821	154	☐	July - August 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3434	PEG 300	ROL
A02586	155	☑	May - June 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3434	Corn Oil	JAG
A05141	156	☑	May - June 2005	Gavage	8	7	190 (±10%)	140 (±10%)	Group	Kliba 3434	Na-Carboxymethylcellulose (0.5%)	KHE
A06513	157	☐	July - August 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3434	Purified water	PAV
A07705	158	☑	July - August 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3434	Bi-distilled water	PAV
A11643	159	☑	August - September 2005	Intravenous	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3434	0.9% pysiological saline	PAV
A11834	160	☐	June - July 2005	Feeding	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3434	Diet	PAV
A13781	161	☑	August - September 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3434	Corn Oil	JAG
A14668	162	☑	July - August 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	KHE
A15131	163	☐	July - August 2005	Gavage	6	7	150 - 180	125 - 150	Group	Kliba 3433	Carboxymethylcellulose	SPH
A16198	164	☐	August - September 2005	Feeding	6	5	150 (±20%)	125 (±20%)	Group	Kliba 3433	Diet	ROL
A17728	165	☐	September - November 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	SPH

Historical Control Data on Histological Findings in 28-days Studies in RccHan^{TM}: Wist, Wistar Hannover Rats, Recovery

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima-tization (days)	Body Weight: Delivery (g) M	F	Housing	Diet	Vehicle	Pathologist
A17908	166	☐	September - October 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	0.4% aqueous solution of ascorbic acid	ROL
A20351	167	☑	September - October 2005	Feeding	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Diet	PAV
A20698	168	☐	August - September 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	MAM
A21407	169	☑	August - September 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	ROL
A21846	170	☑	October - November 2005	Intravenous	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	0.9% pysiological saline	PAV
A27246	171	☐	October - November 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	ROL
A28765	172	☐	October - November 2005	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	ROL
A36742	173	☐	December - January 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	BDK
A41196	174	☑	December 2005 - January 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	VOO
A09448	175	☑	May - June 2006	Gavage	6	10	150 (±20%)	125 (±20%)	Group	Kliba 3433	Methyl Cellulose	WEK
A43097	176	☑	February - March 2006	Gavage	6	7	134.2-164.9	115.5-135.7	Group	Kliba 3433	1% Carboxymethylcellulose	PAV
A43626	177	☐	January - February 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	BDK
A44717	178	☑	March - April 2006	Semiocclusive		6	200 - 300	200 - 300	Group	Kliba 3433	CMC	PAV
A44886	179	☐	July - August 2006	Injection & Gavage	3	6	approx. 40	approx. 30	Group	Kliba 3433	1% Tween 80 in bidestilled water	WEK
A45336	180	☑	January - February 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	PAV
A46620	181	☑	May - June 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	MAM
A47632	182	☑	January - February 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	ROL
A50477	183	☑	March - April 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	PAV
A53842	184	☑	April - May 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	PAV
A54134	185	☐	March - April 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	BDK
A54347	186	☐	March - April 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	WEK

Historical Control Data on Histological Findings in 28-days Studies in RccHan^{TM}: Wist, Wistar Hannover Rats, Recovery

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima-tization (days)	Body Weight: Delivery (g) M	Body Weight: Delivery (g) F	Housing	Diet	Vehicle	Pathologist
A58408	187	☐	July - August 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	TAT
A62594	188	☑	April - May 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	HJC
A62943	189	☑	July - August 2006	Subcutaneous	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Tween 80; Carboxylmethylcellulose; Benzyl alcohol; 0.9% physiological saline	PAV
A65081	190	☑	July - August 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	JAG
A70086	191	☐	June - July 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	MAM
A70222	192	☑	May - June 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	PAV
A71324	193	☐	April - May 2006	Gavage	6	7	151 (±20%)	/	Group	Kliba 3433	Purified water	KHE
A73708	194	☑	July - August 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	KHE
A73991	195	☑	June - July 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	0.5% Carboxylmethylcellulose	JAG
A74518	196	☐	May - June 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	BDK
A74970	197	☑	July - August 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	PAV
A80932	198	☐	August - October 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	PAV
A85915	199	☐	September - October 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	KHE
A89640	200	☐	September - October 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	ROL
A90303	201	☑	October - Novenber 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	PAV
A93104	202	☑	October - Novenber 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Methylcellulose; 0.5% in water; Polysorbate 80 (Tween 80)	PAV
A93734	203	☑	December 2006 - January 2007	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	BDK
A96467	204	☑	October - Novenber 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	BDK
A98662	205	☐	October - Novenber 2006	Gavage	6	5	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	HJC
B04882	206	☐	December 2006 - January 2007	Semiocclusive	♂ : 7 - 9 ♀ : 10 - 12	7	180 - 220 (±20%)	181 - 220 (±20%)	Group	Kliba 3433	Ethanol puriss	KHE
B05512	207	☑	December 2006 - January 2007	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	KHE

Historical Control Data on Histological Findings in 28-days Studies in RccHan^{TM}: Wist, Wistar Hannover Rats, Recovery

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima-tization (days)	Body Weight: Delivery (g) M	Body Weight: Delivery (g) F	Housing	Diet	Vehicle	Pathologist
B08144	208	☐	December 2006 - January 2007	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Hydroxypropylmethylcellulose 0.2%	HJC
B08008	209	☑	February - March 2007	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Labrasol, Cremophor RH 40, Labrafac Lipophil WL 1349, Plurol Oleique CC	HJC
B09808	210	☐	March - April 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	PEG 300	PAV
B12958	211	☑	February - March 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	PEG 300	TAT
B18966	212	☐	February - March 2007	Feeding	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Diet	BDK
B19800	213	☑	May - June 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	PEG 300	TAT
B21598	214	☐	March - April 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	PEG 300	ROL
B24434	215	☐	June - July 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	PEG 300	BDK
B25874	216	☐	May - June 2007	Feeding	6	5	150 (±20%)	125 (±20%)	Group	Kliba 3433	Diet	SPH
B26572	217	☐	May - June 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Bi-distilled water	BDK
B27494	218	☐	August - September 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Corn Oil	IHI
B31972	219	☑	August - September 2007	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	BDK
B32422	220	☑	May - June 2007	Feeding	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Diet	KHE
858959	221	☐	March - April 2005	Gavage	6	6	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	VOO
B33063	222	☐	August - September 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Corn Oil	TAT
B34481	223	☑	August - September 2007	Bolus intravenous	6	7	150 (±20%)	/	Group	Kliba 3433	Bi-distilled water	TAT
B25234	224	☑	July - August 2007	Subcutaneous	6	5	150 (±20%)	125 (±20%)	Group	Kliba 3433	Diluent for Polysialylated Erythropoietin	HJC
B43525	225	☐	September - October 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Bi-distilled water	BDK
C19984	226	☑	November - December 2008	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Methylcellulose	KRG
763110	227	☐	April - May 2000	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	WEK
770567	228	☑	May - June 2000	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK

Historical Control Data on Histological Findings in 28-days Studies in RccHan™: Wist, Wistar Hannover Rats, Recovery

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima-tization (days)	Body Weight: Delivery (g) M	Body Weight: Delivery (g) F	Housing	Diet	Vehicle	Pathologist
749575	229	☑	October - November 1999	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	WEK
794924	230	☑	28. Dec. 2000 - 22.Febr. 2001	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK
902676	231	☐	30. Apr.1998 - 4 Jun. 1998	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	WEK
849570	232	☑	28. Jul. - 31. Aug. 2003	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Water	WEK
792000	233	☐	01. Nov. - 13 Dec. 2000	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK
B65125	234	☑	December 2007 - Januar 2008	Gavage	7	7	190 (±20%)	150 (±20%)	Group	Kliba 3433	Corn Oil	KOD
B53403	235	☑	October - November 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	PEG 300	TAT
B49184	236	☑	December 2007 - Januar 2008	Gavage	7	5	190 (±20%)	150 (±20%)	Group	Kliba 3433	Refined Heavy Parafinic Diluent Mineral Oil	TAT
848428	237	☑	May - June 2003	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	NED
B46528	238	☑	October - November 2007	Feeding	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Diet	BDK
B55776	239	☑	October - November 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	PEG 300	BDK
B57047	240	☑	October - November 2008	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	PEG 300	BDK
B61648	241	☑	October - November 2007	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	IHI
B62043	242	☑	December 2007 - Januar 2008	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Purified water	IHI
B65485	243	☐	November - December 2007	Semiocclusive	7	4	170 (±20%)	140 (±20%)	Group	Kliba 3433	0.5% (w/v) Carboxymethylcellulose in 0.1% (w/v) aqueous polysorbate 80	TAT
B68872	244	☑	December 2007 - Januar 2008	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Sesam Oil	PAV
B33390	245	☐	April - May 2008	Gavage	7	5	190 (±20%)	150 (±20%)	Group	Kliba 3433	Corn oil	HJC
B57352	246	☐	January - February 2008	Gavage	7	5	190 (±20%)	150 (±20%)	Group	Kliba 3433	0.5% aqueous solution of carboxylmethyl-cellulose and 0.1%Tween 80	WEK
B63450	247	☐	January - February 2008	Gavage	7	5	190 (±20%)	150 (±20%)	Group	Kliba 3433	PEG 300	ROL
B74430	248	☑	August - September 2008	1-hour infusion	7	7	190 (±20%)	150 (±20%)	Group	Kliba 3433	Sterile saline (0.9% w/v NaCl)	PIAL
B75958	249	☐	March - April 2008	Subcutaneous	6	5	150 (±20%)	125 (±20%)	Group	Kliba 3433	NTS with polyethylene (HDPE)	IHI

Historical Control Data on Histological Findings in 28-days Studies in RccHan™: Wist, Wistar Hannover Rats, Recovery

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima-tization (days)	Body Weight: Delivery (g) M	Body Weight: Delivery (g) F	Housing	Diet	Vehicle	Pathologist
B83182	250	☐	January - February 2008	Semiocclusive	♂ : 10 - 12 ♀ : 7 - 9	7	180 - 220 (±20%)	181 - 220 (±20%)	Group	Kliba 3433	mixture of 70% Ethanol and 30% purified water (v/v)	IHI
B85364	251	☑	May - June 2009	Gavage	7	6	190 (±20%)	150 (±20%)	Group	Kliba 3433	Corn Oil	TAT
C35431	252	☐	January - February 2009	Gavage	6	4	200 (±20%)	140 (±20%)	Group	Kliba 3433	0.5% CMC	PAV
B88334	253	☑	June - July 2008	Semiocclusive	7	5	190 (±20%)	150 (±20%)	Group	Kliba 3433	Colourless, opaque ointment formulation 70:30 White Soft Paraffin: Miglyol 812.	HJC
B97233	254	☑	August - September 2008	Gavage	7	7	190 (±20%)	150 (±20%)	Group	Kliba 3433	SN11 formulation	KHE
C02215	255	☐	August - September 2008	Gavage	6	8	150 (±20%)	125 (±20%)	Group	Kliba 3433	Lc15-0444 Tartrate	PAV
C09274	256	☐	December 2008 - Januar 2009	Gavage	7	7	190 (±20%)	150 (±20%)	Group	Kliba 3433	Corn Oil	IHI
C12301	257	☑	December 2008 - Januar 2009	Gavage	7	5	190 (±20%)	150 (±20%)	Group	Kliba 3433	PEG 300	HJC
C21075	258	☐	December 2008 - Januar 2009	Semiocclusive	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Bi-distilled water	KHE
C26418	259	☑	December 2008 - Januar 2009	Gavage	7	5	190 (±20%)	150 (±20%)	Group	Kliba 3433	PEG 300	TAT
844476	260	☐	June - July 2002	Gavage	6	8	150 (±20%)	125 (±20%)	Group	Kliba 3433	0.2% HPMC	WEK
605711	261	☐	October - November 1997	Intravenous	7	4	190 (±20%)	145 (±20%)	Group	Kliba 3433	Physiological saline (0.9% NaCl)	WEK
605722	262	☐	December 2007 - Januar 2008	Gavage	4	7	70 (±20%)	65 (±20%)	Group	Kliba 3433	Physiological saline (0.9% NaCl)	WEK
843550	263	☐	December 1997 - Januar 1998	Inhalation	♂ : 6 - 8 ♀ : 8 - 10	14	180 - 200	181 - 200	Group	Kliba 3433	Lactose	JAG
733050	264	☐	September - October 1999	Gavage	4	7	70 (±20%)	65 (±20%)	Group	Kliba 3433	Physiological saline (0.9% NaCl)	RON
761782	265	☐	August - September 2000	Gavage	5	7	120 (±20%)	100 (±20%)	Group	Kliba 3433	Physiological saline (0.9% NaCl)	WEK
707242	266	☐	February - March 1999	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK
847755	267	☑	March - April 2003	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	SPH
817165	268	☐	August - September 2001	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	WEK
811732	269	☐	April - May 2001	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK
846594	270	☐	January - February 2003	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK

Historical Control Data on Histological Findings in 28-days Studies in RccHan^{TM}: Wist, Wistar Hannover Rats, Recovery

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima-tization (days)	Body Weight: Delivery (g) M	F	Housing	Diet	Vehicle	Pathologist
847074	271	☐	January - February 2003	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK
695913	272	☐	March-April 1999	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK
386921	273	☑	February - March 1995	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK
846770	274	☑	March-April 2003	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	BBA
847835	275	☑	February - March 2003	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	WEK
364476	276	☐	February - March 1994	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	WEK
807581	277	☑	May - June 2001	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	KOD
818403	278	☐	August - September 2001	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	PEG 300	WEK
677441	279	☐	September - October 1999	Inhalation	♂ : 8-10 ♀ : 10-12	7	180 - 200	180 - 200	Group	Kliba 3433	HFA Placebo Formulation in Metered Dose Inhalers (MDI)	WEK
697781	280	☑	July - August 1999	Inhalation	♂ : 6-8 ♀ : 10 12	7	180 - 200	180 - 200	Group	Kliba 3433	Vehicle of Budesonide unit dose	WEK
B64710	281	☑	October - November 2007	Infusion	7	5	300(±20%)		Group	Kliba 3433	5% Glucose solution	WEK
298866	282	☐	June - July 1991	Gavage	6	7	180 (±20%)	160 (±20%)	Group	Kliba 3433	Polyethylene glycol, PEG 400	WEK
337476	283	☑	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	n.d.	WEK
346577	284	☑	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	n.d.	WEK
369808	285	☐	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	n.d.	WEK
375322	286	☑	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	Group	n.d.	Bi-distilled water	WEK
382588	287	☑	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	Corn Oil	WEK
C31537	288	☑	January - March 2009	Gavage	7	7	190 (±20%)	150 (±20%)	Group	Kliba 3433	Corn Oil	WEK
391296	289	☐	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	Bi-distilled water	WEK
395820	290	☑	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	Polyethylene glycol, PEG 400	WEK
605024	291	☑	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	Bi-distilled water	WEK

Historical Control Data on Histological Findings in 28-days Studies in RccHan^{TM}: Wist, Wistar Hannover Rats, Recovery

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima-tization (days)	Body Weight: Delivery (g) M	Body Weight: Delivery (g) F	Housing	Diet	Vehicle	Pathologist
650845	292	☐	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	n.d.	WEK
652601	293	☑	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	Bi-distilled water	WEK
666797	294	☑	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	Bi-distilled water	WEK
733050	295	☐	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	Physiological saline (0.9% NaCl)	WEK
733882	296	☑	n.d.	Inhalation	n.d.	n.d.	n.d.	n.d.	Group	n.d.	n.d.	WEK
746223	297	☑	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	n.d.	WEK
761782	298	☐	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	Group	n.d.	n.d.	WEK
773010	299	☑	n.d.	Inhalation	n.d.	n.d.	n.d.	n.d.	Group	n.d.	n.d.	WEK
780772	300	☐	n.d.	Inhalation	n.d.	n.d.	n.d.	n.d.	Group	n.d.	n.d.	WEK
B68872	301	☑	Dec.2007 - Jan. 2008	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Clopidogrel besylate	PAV
C32123	302	☑	Mar 2009-May 2009	Gavage	7	5	190 (±20%)	150 (±20%)	Group	Kliba 3433	Polyethylene glycol, PEG 300	TAT
C00090	303	☑	Nov. 2008 - Dec. 2008	Inhalation	8	5	n. d.	n. d.	Group	Kliba 3433	Air	KOD
C21525	304	☐	Jan. 2009 - Feb. 2009	Subcutaneous	7	7	190 (±20%)	150 (±20%)	Individually	Kliba 3433	Physiological saline (0.9% NaCl)	IHI
C44982	305	☐	July 2009 - November 2009	Gavage	11	n.d.	275 - 325	180 - 220	Individually	Kliba 3433	PEG 300	PAC
C64040	306	☐	October 2009 - February 2010	Feeding	7	8	190 (±20%)	only Male	Group	Teklad 2014	Diet	WEK
C72048	307	☐	November 2009 - February 2010	Dermal	7	5	170 (±20%)	140 (±20%)	Individually	Kliba 3433	0.5% CMC	PAC
B31713	308	☐	April 2007 - July 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	0.5% Methylcellulose	KRG
C55951	309	☐	October 2009 - January 2010	Gavage	7	5	190 (±20%)	150 (±20%)	Group	Kliba 3433	Bi-distilled water	HJC
B77275	310	☐	n.d.	Gavage	n.d.	n.d.	n.d.	n.d.	n.d.	n.d.	1% Metoceol in distilled water	WEK
B41793	311	☐	June 2007 - July 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Na-Acetate Buffer pH 4,5	KRG
B41804	312	☐	June 2007 - July 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Na-Acetate Buffer pH 4,5	KRG

Historical Control Data on Histological Findings in 28-days Studies in RccHan™: Wist, Wistar Hannover Rats, Recovery

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima-tization (days)	Body Weight: Delivery (g) M	F	Housing	Diet	Vehicle	Pathologist
B47992	313	☐	July 2007 - August 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Na-Acetate Buffer pH 4,5	KRG
C31190	314	☐	Jan. 2009 - July. 2009	Subcutaneous	6	7	150 (±20%)	125 (±20%)	Individually	Kliba 3433	High-density polyethene	TAT
C57852	315	☐	September 2009	Feeding	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Diet	KHE
B31724	316	☐	May 2007 - June 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Acetat Buffer, pH 4,5	KRG
B47968	317	☐	July 2007 - August 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Na-Acetate Buffer pH 4,5	KRG
B05872	318	☐	January 2007 -April 2007	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Corn Oil	KRG
858919	319	☐	March 2005 -January 2006	Gavage	6	7	142.6-153.5	116.0-129.1	Group	Kliba 3433	Dried Corn Oil	PAV
B08741	320	☐	February 2008	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Corn Oil	KOD
B90685	321	☐	April 2008 - July 2008	Gavage	6	5	n.d.	n.d.	Individually	Teklad 2014C	Bi-distilled water	WEK
C05167	322	☑	April 2008 - September 2008	Gavage	6	5	n.d.	n.d.	Individually	Teklad 2014C	Arachis Oil	WEK
848192	323	☑	July 2003 - September 2003	Inhalation	6 - 10	2	180 - 200	180 - 200	Group	Kliba 3433	Lactose/Mg Stearate	WEK
B47970	324	☐	July 2007 - November 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Na-Acetate Buffer pH 4,5	KRG
B47981	325	☐	July 2007 - November 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Na-Acetate Buffer pH 4,5	KRG
B50174	326	☐	August 2007 - December 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Na-Acetate Buffer pH 4,0	KRG
C32898	327	☑	January 2009 -April 2007	Gavage	7	7	170 (±20%)	130 (±20%)	Group	Kliba 3433	0,5% Methylcellulose	IHI
A25435	328	☑	February 2006 - October 2007	Gavage	6	7	127.1 - 153.3	112.3 - 133.0	Group	Kliba 3433	Sterile water	JAG
857411	329	☐	January 2005 - May 2005	Feeding	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Diet	KRG
B12047	330	☐	July 2007 - November 2007	Gavage	7	7	170 (±20%)	140 (±20%)	Group	Kliba 3433	Corn Oil	KOD
B25064	331	☑	March 2007 - July 2007	Gavage	6	7	150 (±20%)	120 (±20%)	Group	Kliba 3433	Carboxymethyl cellulose	PAV
A19484	332	☑	August 2005 - November 2005	Gavage	6	7	142 - 157	114 - 129	Group	Kliba 3433	Bi-distilled water	GPE
B09101	333	☐	January 2007 - June 2007	Gavage	7	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Bi-distilled water	KOD

Historical Control Data on Histological Findings in 28-days Studies in RccHan^{TM}: Wist, Wistar Hannover Rats, Recovery

Study Number	ID Number	Recovery	Data of Performance	Study Type	Age/ Delivery (weeks)	Pretest/ Acclima-tization (days)	Body Weight: Delivery (g) M	Body Weight: Delivery (g) F	Housing	Diet	Vehicle	Pathologist
B33873	334	☐	February 2008 - April 2008	Gavage	7	7	190 (±20%)	150 (±20%)	Group	Kliba 3433	Polyethylene glycol PEG 300	KOD
B01056	335	☐	November 2006 - April 2007	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Polyethylene glycol PEG 300	KOD
B72101	336	☐	Feb. 2008 - September 2008	Semiocclusive	7	7	170 (±20%)	140 (±20%)	Individually	Kliba 3433	only bandaged	KOD
A46708	337	☑	May 2006 - September 2006	Gavage	6	7	150 (±20%)	125 (±20%)	Group	Kliba 3433	Polyethylene glycol PEG 300	KOD
C19578	338	☑	January 2009 - February 2009	Gavage	7	7	190 (±20%)	150 (±20%)	Group	Kliba 3433	Bi-distilled water	KOD
B68095	339	☑	Dec. 2007 - February 2008	Gavage	7	7	190 (±20%)	150 (±20%)	Group	Kliba 3433	Corn Oil	KRG
C19466	340	☑	Januar 2009 - February 2009	Gavage	7	8	190 (±20%)	150 (±20%)	Group	Kliba 3433	Bi-distilled water	KOD
	341											
	342											
	343											
	344											
	345											
	346											
	347											

n.d. =no data

Pathologists:

BDK:	Dr. med. vet. K. Bodiè, Toxicologic Pathologist
BSC:	Dr. med. vet. B. Schlotke, Veterinary Pathologist
CJS:	Dr. med. C. Springall, Pathologist
GPZ:	Dr. med. vet. G. Pappritz, Veterinary Pathologist
GPE:	Dr. G. Pohlmeyer-Esch
HHW:	Dr. med. vet. H. Westen, Veterinary Pathologist
HJC:	Dr. med. vet. H.J. Chevalier, Veterinary Pathologist
IHI:	Dr. med. vet. Iwata Hijiri, Veterinary Pathologist
JAG:	Dr. med. vet. J. Armstrong, Veterinary Pathologist
JAW:	Dr. med. vet. J. Walberg, Veterinary Pathologist
JMA:	Dr. med. J. Aluma, Pathologist
KHE:	Dr. med. vet. K. Heider, Veterinary Pathologist
KOD:	Dr. med. Daniel Konrad, Toxicologic Pathologist
KRG:	Dr. med. vet. Dr. G. Krinke, Veterinary Pathologist
LE:	Dr. B. Lenz (Sponsor pathologist)
MAM:	Dr. med. vet. Martland Malcome, Veterinary Pathologist
MIP:	Dr. med. vet. P. Millar, Veterinary Pathologist
NED:	Dr. med. vet. D. Nehrbass, Veterinary Pathologist
PAV:	Dr. med. vet. V. Pace, Veterinary Pathologist
PIAL:	Dr. med. vet. Alessandra Piersigilli, Toxicologic Pathologist
RHA:	Dr. R.H. Alison, Toxicologic Pathologist
ROL:	Dr. med. L. Romeo, Pathologist
RON:	Dr. med. vet. N. Robert, Veterinary Pathologist
RUD:	Prof. Dr. med. vet. R. Rudolph, Veterinary Pathologist
SPH:	Dr. med. vet. P. Schätti, Veterinary Pathologist
TAT:	Dr. med. vet. T. Razinger, Toxicologic Pathologist
THK:	Dr. med. vet.T. Hodge, Veterinary Pathologist
VOO:	Dr. med. vet. O. Vogel, Veterinary Pathologist
WEK:	Dr. rer. nat. K. Weber, Toxicologic Pathologist
WIL:	Dr. med. vet. J. T. Wilson, Veterinary Pathologist
WLA:	Dr. med. vet. A. Waldvogel, Veterinary Pathologist
WRJ:	Dr. med. vet. J. Wright, Veterinary Pathologist

Organ	Page	Organ	Page
Brain	4	Pancreas	21
Cerebellum	4	Liver	22 , 23
Brain stem/midbrain	4	Tongue	24
Medulla oblongata	4	Esophagus	24
Cerebrum	5	Stomach	25 , 26
Pons	5	Forestomach	26
Telencephalon	5	Glandular stomach	27
Spinal cord	6	Duodenum	27
Cervical spinal cord	6	Jejunum	27
Lumbar spinal cord	6	Ileum	28
Midthoracic spinal cord	7	Peyer’s patches NOS	28
Sciatic nerve	7	Peyer’s patches Jejunum	29
Tibial nerve	7	Peyer’s patches Ileum	29
Optic nerve	7	Cecum	30
Eyes	8	Colon	30
Harderian glands	9	Rectum	31
Exorbital lacrimal glands	9	Salivary glands	31
Aorta	9	Parotid salivary glands	32
Heart	10	Submandibular salivary glands	32
Heart / Auricles	10	Sublingual salivary glands	33
Nasopharyngeal duct	11	Urinary bladder	33
Nasal cavity	11	Urether	34
Nasal cavity, level 1	11	Kidneys	34 , 35
Nasal cavity, level 2	11	Skin	36
Nasal cavity, level 3	12	Mammary gland	37
Nasal cavity, level 4	12	Testes	37
Pharynx	12	Epididymides	38
Larynx	13	Seminal vesicles	38
Larynx, level 2	13	Prostate	38
Larynx, level 3	13	Coagulating glands	38
Larynx, level 4	14	Ovaries	39
Larynx, level 5	14	Oviducts	39
Larynx, level 6	15	Uterus	39
Trachea	15	Vagina	40
Lungs	16 , 17	Bone marrow	40
Tracheal bifurcation, carina	17	Bone marrow - sternum	41
Main bronchi	17	FemurBone marrow - femur	41
Pituitary	18	Mesenteric lymph nodes	42
Adrenals NOS	18	Mandibular lymph nodes	43
Adrenal cortex	19	Mediastinal lymph nodes	44
Adrenal medulla	19	Other lymph nodes	44
Thyroid glands	20	Thymus	45
Parathyroid glands	20	Spleen	46

Organ	Page
Joint	46
Bone	47
Skeletal muscle	47
Body cavities	48
Adipose tissue	48
Injection sides	49
Injection sides- right	49
Injection sides- left	50
Injection site: tail	50
Retroorbital tissue	50
Treated skin	51
Untreated skin	51
Ears	51
Tail	51
Infusion site	52

Brain

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	895					
Neuronale fixation artefacts	5	0.56	0.56	7.47	0.00	100.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	885					
Neuronale fixation artefacts	5	0.56	0.56	7.52	0.00	100.00

Cerebellum

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	748					
Hemorrhage	2	0.27	0.27	2.32	0.00	20.00
Satellitosis	1	0.13	0.14	1.64	0.00	20.00
Degeneration	1	0.13	0.14	1.64	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	738					
Hemorrhage	2	0.27	0.27	2.33	0.00	20.00
Satellitosis	0	0.00	0.00	0.00	0.00	0.00
Degeneration	0	0.00	0.00	0.00	0.00	0.00

Brain stem/midbrain

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	592					

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	587					

Medulla oblongata

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	529					
Hemorrhage	1	0.19	0.19	1.94	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	519					
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00

Cerebrum

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	718					
Dilation	0	0.00	0.00	0.00	0.00	0.00
Hemorrhage	3	0.42	0.52	4.35	0.00	40.00
Neuronophagia	0	0.00	0.00	0.00	0.00	0.00
Nervus opticus degeneration	1	0.14	0.14	1.68	0.00	20.00
Malformation	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	708					
Dilation	2	0.28	0.29	2.38	0.00	20.00
Hemorrhage	3	0.42	0.43	3.77	0.00	40.00
Neuronophagia	0	0.00	0.00	0.00	0.00	0.00
Nervus opticus degeneration	0	0.00	0.00	0.00	0.00	0.00
Malformation	1	0.14	0.14	1.69	0.00	20.00

Pons

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	614					

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	604					

Telencephalon

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	493					
Gliosis	0	0.00	0.00	0.00	0.00	0.00
Hydrocephalus	0	0.00	0.00	0.00	0.00	0.00
Ventricular dilation	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	488					
Gliosis	1	0.20	0.20	2.02	0.00	20.00
Hydrocephalus	1	0.20	0.20	2.02	0.00	20.00
Ventricular dilation	1	0.20	0.20	2.02	0.00	20.00

Spinal cord

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	855					
Fixation artefact	1	0.12	0.12	1.53	0.00	20.00
Neuronal vacuoles	1	0.12	0.12	1.53	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	850					
Fixation artefact	3	0.35	0.35	4.60	0.00	60.00
Neuronal vacuoles	0	0.00	0.00	0.00	0.00	0.00

Cervical spinal cord

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	251					
Hemorrhage(s)	1	0.40	0.44	2.98	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	246					
Hemorrhage(s)	0	0.00	0.00	0.00	0.00	0.00

Lumbar spinal cord

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	236					
Hemorrhage(s)	2	0.85	0.95	6.17	0.00	40.00
Satellitosis	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	231					
Hemorrhage(s)	0	0.00	0.00	0.00	0.00	0.00
Satellitosis	1	0.43	0.49	3.12	0.00	20.00

Midthoracic spinal cord

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	236					
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	231					
Hemorrhage	1	0.43	0.49	3.12	0.00	20.00

Sciatic nerve

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	946					
Ectopic neurons	1	0.11	0.11	1.47	0.00	20.00
Nerve fiber degeneration	36	3.81	3.89	9.44	0.00	40.00
Neuronophagia	1	0.11	0.11	1.47	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	936					
Ectopic neurons	1	0.11	0.07	0.92	0.00	12.50
Nerve fiber degeneration	67	7.16	7.50	16.44	0.00	100.00
Neuronophagia	1	0.11	0.11	1.48	0.00	20.00

Tibial nerve

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	20					
Nerve fiber degeneration	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	20					
Nerve fiber degeneration	1	5.00	5.00	10.00	0.00	20.00

Optic nerve

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	330					

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	335					

Eyes

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	345					
Retinal rosettes	2	0.58	0.59	3.40	0.00	20.00
Hemorrhage	39	11.30	11.36	22.74	0.00	80.00
Mononuclear cell foci	2	0.58	0.59	3.40	0.00	20.00
Inflammation	15	4.35	4.08	13.09	0.00	80.00
Inflammation: sclera	0	0.00	0.00	0.00	0.00	0.00
Conjunctivitis	1	0.29	0.29	2.43	0.00	20.00
Keratitis	2	0.58	1.76	12.33	0.00	100.00
Retinal degeneration	2	0.58	0.59	3.40	0.00	20.00
Scleritis	0	0.00	0.00	0.00	0.00	0.00
Iridocyclitis	0	0.00	0.00	0.00	0.00	0.00
Lenticular degeneration	0	0.00	0.00	0.00	0.00	0.00
Panophtalmia	1	0.29	1.47	12.13	0.00	100.00
Peribulbar lymphang.	0	0.00	0.00	0.00	0.00	0.00
Phtisis bulbi	0	0.00	0.00	0.00	0.00	0.00
Retinal dysplasia	1	0.29	0.29	2.43	0.00	20.00
Periorbital inflammation	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	345					
Retinal rosettes	6	1.74	1.76	7.52	0.00	40.00
Hemorrhage	36	10.43	11.84	23.27	0.00	100.00
Mononuclear cell foci	1	0.29	0.29	2.43	0.00	20.00
Inflammation	24	6.96	7.06	15.36	0.00	60.00
Inflammation: sclera	1	0.29	0.18	1.52	0.00	12.50
Conjunctivitis	2	0.58	0.59	3.40	0.00	20.00
Keratitis	1	0.29	1.47	12.13	0.00	100.00
Retinal degeneration	9	2.61	2.65	13.34	0.00	100.00
Scleritis	3	0.87	1.03	6.50	0.00	50.00
Iridocyclitis	1	0.29	0.29	2.43	0.00	20.00
Lenticular degeneration	2	0.58	0.59	3.40	0.00	20.00
Panophtalmia	0	0.00	0.00	0.00	0.00	0.00
Peribulbar lymphang.	1	0.29	0.29	2.43	0.00	20.00
Phtisis bulbi	1	0.29	1.47	12.13	0.00	100.00
Retinal dysplasia	0	0.00	0.00	0.00	0.00	0.00
Periorbital inflammation	2	0.58	0.59	4.85	0.00	40.00

Harderian glands

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	261					
Porphyrin deposition	52	19.92	16.18	32.24	0.00	100.00
Hemorrhage	28	10.73	7.80	21.28	0.00	80.00
Atrophy, azinar	1	0.38	0.25	1.77	0.00	12.50
Inflammation	22	8.43	5.60	15.22	0.00	62.50
Mononuclear cell foci	0	0.00	0.00	0.00	0.00	0.00
Inflammatory cell foci	5	1.92	2.00	6.06	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	260					
Porphyrin deposition	56	21.54	17.05	31.48	0.00	100.00
Hemorrhage	24	9.23	7.85	21.44	0.00	100.00
Atrophy, azinar	0	0.00	0.00	0.00	0.00	0.00
Inflammation	21	8.08	6.78	18.49	0.00	100.00
Mononuclear cell foci	3	1.15	0.38	2.65	0.00	18.75
Inflammatory cell foci	1	0.38	0.50	3.54	0.00	25.00

Exorbital lacrimal glands

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	241					
Hemorrhage	3	1.24	2.98	15.02	0.00	100.00
Harderian alteration	9	3.73	5.37	16.42	0.00	100.00
Acinar hypertrophy	5	2.07	0.66	4.56	0.00	31.25

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	244					
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00
Harderian alteration	1	0.41	0.43	2.95	0.00	20.00
Acinar hypertrophy	0	0.00	0.00	0.00	0.00	0.00

Aorta

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	303					

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	303					

Heart

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	966					
Osseus metaplasia	0	0.00	0.00	0.00	0.00	0.00
Cartilaginous metaplasia	3	0.31	0.31	4.34	0.00	60.00
Lymphangectasis	2	0.21	0.21	2.04	0.00	20.00
Mast cell infiltration	3	0.31	0.31	4.34	0.00	60.00
Mononuclear cell foci	118	12.22	12.35	18.52	0.00	80.00
Myofibrosis/necrosis	22	2.28	2.30	10.00	0.00	100.00
Myocardial necrosis	24	2.48	2.45	7.66	0.00	50.00
Myocardial inflammation	3	0.31	0.31	2.49	0.00	20.00
Myocardial fibrosis	7	0.72	0.66	3.52	0.00	20.00
Mineralization	0	0.00	0.00	0.00	0.00	0.00
Progressive myocardiopathy	1	0.10	0.10	1.45	0.00	20.00
Hemorrhage	1	0.10	0.17	2.41	0.00	33.33

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	951					
Osseus metaplasia	1	0.11	0.11	1.46	0.00	20.00
Cartilaginous metaplasia	1	0.11	0.11	1.46	0.00	20.00
Lymphangectasis	1	0.11	0.11	1.46	0.00	20.00
Mast cell infiltration	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	55	5.78	5.84	12.09	0.00	60.00
Myofibrosis/necrosis	10	1.05	1.06	6.45	0.00	60.00
Myocardial necrosis	2	0.21	0.21	2.06	0.00	20.00
Myocardial inflammation	1	0.11	0.11	1.46	0.00	20.00
Myocardial fibrosis	1	0.11	0.11	1.46	0.00	20.00
Mineralization	1	0.11	0.11	1.46	0.00	20.00
Progressive myocardiopathy	0	0.00	0.00	0.00	0.00	0.00
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00

Heart / Auricles

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	65					

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	65					

Nasopharyngeal duct

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	64					
Goblet cell proliferation	1	1.56	2.00	6.32	0.00	20.00
Mucous plug	1	1.56	2.00	6.32	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	64					
Goblet cell proliferation	1	1.56	2.00	6.32	0.00	20.00
Mucous plug	0	0.00	0.00	0.00	0.00	0.00

Nasal cavity

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	228					

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	228					

Nasal cavity, level 1

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	103					
Goblet cell proliferation	2	1.94	0.69	2.95	0.00	12.50
Cellullar detritus	1	0.97	1.11	4.71	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	103					
Goblet cell proliferation	5	4.85	4.79	10.92	0.00	40.00
Cellullar detritus	0	0.00	0.00	0.00	0.00	0.00

Nasal cavity, level 2

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	103					
Goblet cell proliferation	10	9.71	9.86	21.77	0.00	80.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	103					
Goblet cell proliferation	6	5.83	6.25	19.18	0.00	80.00

Nasal cavity, level 3

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	106					
Mononuclear cell foci	1	0.94	0.69	2.95	0.00	12.50
Eosinophile material	1	0.94	1.11	4.71	0.00	20.00
Goblet cell proliferation	0	0.00	0.00	0.00	0.00	0.00
Lymphoid hyperplasia	1	0.94	1.11	4.71	0.00	20.00
Mineralization	1	0.94	1.11	4.71	0.00	20.00
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	106					
Mononuclear cell foci	1	0.94	0.69	2.95	0.00	12.50
Eosinophile material	0	0.00	0.00	0.00	0.00	0.00
Goblet cell proliferation	1	0.94	1.11	4.71	0.00	20.00
Lymphoid hyperplasia	1	0.94	1.11	4.71	0.00	20.00
Mineralization	0	0.00	0.00	0.00	0.00	0.00
Hemorrhage	1	0.94	1.11	4.71	0.00	20.00

Nasal cavity, level 4

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	93					
Goblet cell proliferation	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	93					
Goblet cell proliferation	2	2.15	2.50	10.00	0.00	40.00

Pharynx

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	61					
Epithelial vacuolization	1	1.64	2.00	6.32	0.00	20.00
Mononuclear cell foci	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	61					
Epithelial vacuolization	1	1.64	2.00	6.32	0.00	20.00
Mononuclear cell foci	1	1.64	2.00	6.32	0.00	20.00

Larynx

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	237					
Glandular dilation	3	1.27	1.28	8.75	0.00	60.00
Mononuclear cell foci	0	0.00	0.00	0.00	0.00	0.00
Inflammatory cell foci	11	4.64	4.68	13.33	0.00	60.00
Granuloma	1	0.42	0.43	2.92	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	237					
Glandular dilation	5	2.11	2.13	14.59	0.00	100.00
Mononuclear cell foci	1	0.42	0.43	2.92	0.00	20.00
Inflammatory cell foci	5	2.11	2.13	9.54	0.00	60.00
Granuloma	0	0.00	0.00	0.00	0.00	0.00

Larynx, level 2

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	59					
Inflammation	1	1.69	2.22	6.67	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	59					
Inflammation	0	0.00	0.00	0.00	0.00	0.00

Larynx, level 3

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	59					
Dissecated secretion	1	1.69	0.69	2.08	0.00	6.25
Mononuclear cell foci	1	1.69	1.39	4.17	0.00	12.50
Granuloma	1	1.69	0.69	2.08	0.00	6.25

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	59					
Dissecated secretion	1	1.69	0.69	2.08	0.00	6.25
Mononuclear cell foci	1	1.69	1.39	4.17	0.00	12.50
Granuloma	0	0.00	0.00	0.00	0.00	0.00

Larynx, level 4

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	8					
Hemorrhage in lumen	0	0.00	0.00	0.00	0.00	0.00
Dissecated secretion	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	3	37.50	37.50	0.00	37.50	37.50
Granuloma	1	12.50	12.50	0.00	12.50	12.50
Inflammation	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	14					
Hemorrhage in lumen	0	0.00	0.00	0.00	0.00	0.00
Dissecated secretion	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	1	7.14	7.14	0.00	7.14	7.14
Granuloma	0	0.00	0.00	0.00	0.00	0.00
Inflammation	0	0.00	0.00	0.00	0.00	0.00

Larynx, level 5

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	6					
Hemorrhage in lumen	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	2	33.33	33.33	0.00	33.33	33.33
Granuloma	0	0.00	0.00	0.00	0.00	0.00
Inflammation	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	9					
Hemorrhage in lumen	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	6	66.67	66.67	0.00	66.67	66.67
Granuloma	0	0.00	0.00	0.00	0.00	0.00
Inflammation	0	0.00	0.00	0.00	0.00	0.00

Larynx, level 6

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	51					
Mononuclear cell foci	5	9.80	0.00	0.00	0.00	0.00
Inflammation	1	1.96	2.50	7.07	0.00	20.00
Squamoid epithelium	5	9.80	3.91	11.05	0.00	31.25

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	50					
Mononuclear cell foci	6	12.00	3.13	8.84	0.00	25.00
Inflammation	0	0.00	0.00	0.00	0.00	0.00
Squamoid epithelium	8	16.00	6.25	17.68	0.00	50.00

Trachea

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	926					
Glandular dilation	107	11.56	11.87	20.23	0.00	80.00
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00
Mineralization	0	0.00	0.00	0.00	0.00	0.00
Hyaline inclusions	36	3.89	3.93	16.57	0.00	100.00
Mononuclear cell foci	109	11.77	11.86	21.73	0.00	100.00
Inflammatory cell foci	16	1.73	1.75	9.45	0.00	80.00
Inflammatory exsudate	0	0.00	0.00	0.00	0.00	0.00
Fibrosis	0	0.00	0.00	0.00	0.00	0.00
Glandular hypertrophy	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	916					
Glandular dilation	103	11.24	11.44	20.30	0.00	80.00
Hemorrhage	1	0.11	0.11	1.49	0.00	20.00
Mineralization	2	0.22	0.18	2.48	0.00	33.33
Hyaline inclusions	32	3.49	3.54	14.48	0.00	100.00
Mononuclear cell foci	105	11.46	11.67	22.61	0.00	100.00
Inflammatory cell foci	19	2.07	2.10	11.45	0.00	80.00
Inflammatory exsudate	1	0.11	0.11	1.49	0.00	20.00
Fibrosis	1	0.11	0.11	1.49	0.00	20.00
Glandular hypertrophy	1	0.11	0.11	1.49	0.00	20.00

Lungs

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	961					
Microorganisms	0	0.00	0.00	0.00	0.00	0.00
Intravascular hairs	1	0.10	0.11	1.45	0.00	20.00
Atelectasis	8	0.83	0.84	4.97	0.00	40.00
Emphysema acute	12	1.25	1.08	6.70	0.00	60.00
Congestion	9	0.94	0.95	4.73	0.00	40.00
Hemorrhage	40	4.16	4.07	11.50	0.00	60.00
Thrombosis	1	0.10	0.11	1.45	0.00	20.00
Alveolar crystalls	1	0.10	0.11	1.45	0.00	20.00
Mucoid substance	1	0.10	0.11	1.45	0.00	20.00
Osseous metaplasia	38	3.95	4.10	10.12	0.00	80.00
Vascular mineralization	211	21.96	21.62	27.97	0.00	100.00
Mineralization	24	2.50	2.53	12.08	0.00	80.00
Brownish pigment	0	0.00	0.00	0.00	0.00	0.00
Alveolar histiocytosis	226	23.52	23.01	27.45	0.00	100.00
Mononuclear cell foci	53	5.52	5.58	13.82	0.00	80.00
Perivascular cuffing	19	1.98	2.00	7.57	0.00	40.00
Inflammatory cell foci	13	1.35	1.33	7.06	0.00	80.00
Alveolitis	41	4.27	4.32	13.81	0.00	80.00
Interstitiar inflammation	1	0.10	0.11	1.45	0.00	20.00
Infiltration lymphocytic	6	0.62	0.70	4.00	0.00	33.33
Vasculitis / Perivasculitis	10	1.04	1.12	7.30	0.00	80.00
Abscess	1	0.10	0.11	1.45	0.00	20.00
Granuloma	3	0.31	0.32	2.50	0.00	20.00
Interstitial inflammation	2	0.21	0.21	2.05	0.00	20.00
Inflammation	3	0.31	0.32	2.50	0.00	20.00
Pleural fibrosis	1	0.10	0.11	1.45	0.00	20.00
Lymphoid hyperplasia	32	3.33	3.37	11.87	0.00	60.00
Alveolar hyperplasia	2	0.21	0.21	2.05	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	946					
Microorganisms	1	0.11	0.11	1.46	0.00	20.00
Intravascular hairs	0	0.00	0.00	0.00	0.00	0.00
Atelectasis	5	0.53	0.53	3.23	0.00	20.00
Emphysema acute	12	1.27	1.10	6.43	0.00	60.00
Congestion	2	0.21	0.21	2.06	0.00	20.00
Hemorrhage	12	1.27	1.18	6.28	0.00	60.00
Thrombosis	0	0.00	0.00	0.00	0.00	0.00
Alveolar crystalls	0	0.00	0.00	0.00	0.00	0.00
Mucoid substance	0	0.00	0.00	0.00	0.00	0.00
Osseous metaplasia	30	3.17	3.17	8.64	0.00	60.00
Vascular mineralization	138	14.59	14.25	22.46	0.00	100.00
Mineralization	15	1.59	1.60	8.77	0.00	80.00
Brownish pigment	1	0.11	0.11	1.46	0.00	20.00
Alveolar histiocytosis	217	22.94	22.25	27.47	0.00	100.00
Mononuclear cell foci	37	3.91	3.69	12.17	0.00	80.00
Perivascular cuffing	24	2.54	2.46	11.18	0.00	80.00
Inflammatory cell foci	9	0.95	0.96	4.77	0.00	40.00
Alveolitis	43	4.55	4.56	15.29	0.00	100.00
Interstitiar inflammation	1	0.11	0.11	1.46	0.00	20.00
Infiltration lymphocytic	3	0.32	0.32	2.52	0.00	20.00
Vasculitis / Perivasculitis	1	0.11	0.18	2.44	0.00	33.33
Abscess	0	0.00	0.00	0.00	0.00	0.00
Granuloma	1	0.11	0.11	1.46	0.00	20.00
Interstitial inflammation	1	0.11	0.11	1.46	0.00	20.00
Inflammation	1	0.11	0.11	1.46	0.00	20.00
Pleural fibrosis	0	0.00	0.00	0.00	0.00	0.00
Lymphoid hyperplasia	21	2.22	2.14	9.71	0.00	60.00
Alveolar hyperplasia	0	0.00	0.00	0.00	0.00	0.00

Tracheal bifurcation, carina

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	16					

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	16					

Main bronchi

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	34					

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	34					

Pituitary

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	368					
Cysts	20	5.43	5.70	11.41	0.00	40.00
Cystic Rathke's cleft	5	1.36	1.41	9.75	0.00	80.00
TSH-Cell hypertrophy	2	0.54	0.56	4.75	0.00	40.00
Pars distalis hypertrophy	3	0.82	0.85	7.12	0.00	60.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	358					
Cysts	9	2.51	2.61	6.78	0.00	20.00
Cystic Rathke's cleft	6	1.68	1.74	8.22	0.00	60.00
TSH-Cell hypertrophy	2	0.56	0.58	4.82	0.00	40.00
Pars distalis hypertrophy	0	0.00	0.00	0.00	0.00	0.00

Adrenals NOS

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	879					
Extra adrenal tissue	1	0.11	0.14	1.89	0.00	25.00
Congestion	0	0.00	0.00	0.00	0.00	0.00
Vacuolation	37	4.21	4.29	17.10	0.00	100.00
Mononuclear cell foci	15	1.71	1.77	11.73	0.00	100.00
Change fatty cortical	3	0.34	0.34	3.37	0.00	40.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	870					
Extra adrenal tissue	2	0.23	0.23	2.14	0.00	20.00
Congestion	1	0.11	0.12	1.52	0.00	20.00
Vacuolation	9	1.03	1.04	6.56	0.00	60.00
Mononuclear cell foci	4	0.46	0.46	3.01	0.00	20.00
Change fatty cortical	0	0.00	0.00	0.00	0.00	0.00

Adrenal cortex

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	976					
Extra-adrenal tissue	8	0.82	0.97	5.10	0.00	40.00
Cyst	1	0.10	0.11	1.47	0.00	20.00
Hemorrhage	1	0.10	0.11	1.47	0.00	20.00
Vacuolation	271	27.77	27.90	32.56	0.00	100.00
Congestion	0	0.00	0.00	0.00	0.00	0.00
Angiectasis	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	6	0.61	0.60	3.33	0.00	20.00
Hemopoietic cell foci	1	0.10	0.18	2.46	0.00	33.33
Hypertrophy	0	0.00	0.00	0.00	0.00	0.00
Hypertrophy, zona fasciculata	5	0.51	0.54	5.30	0.00	60.00
Hypertrophy, zona glomerulosa	6	0.61	0.72	5.02	0.00	40.00
Focal hyperplasia / zona glomerulosa	0	0.00	0.00	0.00	0.00	0.00
Capsular fibrosis	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	961					
Extra-adrenal tissue	8	0.83	0.88	4.12	0.00	20.00
Cyst	0	0.00	0.00	0.00	0.00	0.00
Hemorrhage	1	0.10	0.07	0.93	0.00	12.50
Vacuolation	48	4.99	5.27	14.77	0.00	100.00
Congestion	1	0.10	0.11	1.49	0.00	20.00
Angiectasis	3	0.31	0.28	2.22	0.00	20.00
Mononuclear cell foci	10	1.04	1.05	5.32	0.00	40.00
Hemopoietic cell foci	1	0.10	0.11	1.49	0.00	20.00
Hypertrophy	2	0.21	0.22	2.10	0.00	20.00
Hypertrophy, zona fasciculata	5	0.52	0.55	3.90	0.00	40.00
Hypertrophy, zona glomerulosa	4	0.42	0.44	4.19	0.00	40.00
Focal hyperplasia / zona glomerulosa	1	0.10	0.11	1.49	0.00	20.00
Capsular fibrosis	2	0.21	0.22	2.10	0.00	20.00

Adrenal medulla

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	944					
Mononuclear cell foci	0	0.00	0.00	0.00	0.00	0.00
Congestion	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	933					
Mononuclear cell foci	1	0.11	0.11	1.51	0.00	20.00
Congestion	1	0.11	0.11	1.51	0.00	20.00

Thyroid glands

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	944					
Dysplasia	4	0.42	0.43	3.57	0.00	40.00
Ductal remnants	28	2.97	2.99	8.53	0.00	40.00
Cyst epidermal	1	0.11	0.11	1.46	0.00	20.00
Thymic remnants	24	2.54	2.64	7.83	0.00	40.00
Colloid alteration	4	0.42	0.43	3.57	0.00	40.00
Follicular ectasia	1	0.11	0.11	1.46	0.00	20.00
Mononuclear cell foci	6	0.64	0.64	3.53	0.00	20.00
Inflammatory cell foci	1	0.11	0.11	1.46	0.00	20.00
Follicular cell hypertrophy	66	6.99	7.11	21.48	0.00	100.00
Activation	12	1.27	1.28	8.45	0.00	80.00
Hyperplasia c-cell	1	0.11	0.11	1.46	0.00	20.00
Inflammation	1	0.11	0.11	1.46	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	936					
Dysplasia	5	0.53	0.54	4.39	0.00	40.00
Ductal remnants	28	2.99	3.01	8.28	0.00	40.00
Cyst epidermal	0	0.00	0.00	0.00	0.00	0.00
Thymic remnants	39	4.17	4.22	10.30	0.00	60.00
Colloid alteration	4	0.43	0.43	2.92	0.00	20.00
Follicular ectasia	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	1	0.11	0.11	1.47	0.00	20.00
Inflammatory cell foci	0	0.00	0.00	0.00	0.00	0.00
Follicular cell hypertrophy	15	1.60	1.62	6.56	0.00	40.00
Activation	1	0.11	0.11	1.47	0.00	20.00
Hyperplasia c-cell	0	0.00	0.00	0.00	0.00	0.00
Inflammation	0	0.00	0.00	0.00	0.00	0.00

Parathyroid glands

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	924					

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	905					

Pancreas

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	370					
Exocrine atrophy	3	0.81	0.90	4.39	0.00	25.00
Exocrine hyperplasia	0	0.00	0.00	0.00	0.00	0.00
Inflammatory cell foci	2	0.54	0.56	4.71	0.00	40.00
Congestion	2	0.54	1.39	11.79	0.00	100.00
Zymogene decrease	2	0.54	0.56	3.31	0.00	20.00
Apoptosis	2	0.54	0.56	3.31	0.00	20.00
Acinar cell vacuolation	5	1.35	1.39	8.44	0.00	60.00
Ductular proliferation	1	0.27	0.28	2.36	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	359					
Exocrine atrophy	6	1.67	1.68	5.63	0.00	25.00
Exocrine hyperplasia	1	0.28	0.29	2.39	0.00	20.00
Inflammatory cell foci	5	1.39	1.43	5.19	0.00	20.00
Congestion	1	0.28	1.43	11.95	0.00	100.00
Zymogene decrease	1	0.28	0.29	2.39	0.00	20.00
Apoptosis	1	0.28	0.29	2.39	0.00	20.00
Acinar cell vacuolation	4	1.11	1.14	7.53	0.00	60.00
Ductular proliferation	0	0.00	0.00	0.00	0.00	0.00

Liver

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	956					
Anomaly	1	0.10	0.03	0.45	0.00	6.25
Hypoplasia	1	0.10	0.11	1.45	0.00	20.00
Hepatodiaphragmatic herniation	8	0.84	0.74	3.79	0.00	20.00
Congestion	0	0.00	0.00	0.00	0.00	0.00
Glycogen deposition	58	6.07	6.24	21.66	0.00	100.00
Fatty change	183	19.14	19.04	31.34	0.00	100.00
Vacuolation	46	4.81	4.87	15.63	0.00	100.00
Pigment	4	0.42	0.42	4.59	0.00	60.00
Extramedullary hemopoiesis	73	7.64	7.88	15.47	0.00	100.00
Sinusoidal dilation	0	0.00	0.00	0.00	0.00	0.00
Peribiliary mononuclear	2	0.21	0.21	2.91	0.00	40.00
Hemosiderin	0	0.00	0.00	0.00	0.00	0.00
Hepatocellular pigment	1	0.10	0.03	0.45	0.00	6.25
Inflammatory cell foci	701	73.33	72.46	35.19	0.00	100.00
Multinuclear giant cell(s)	0	0.00	0.00	0.00	0.00	0.00
Peribiliar inflammation	4	0.42	0.42	2.89	0.00	20.00
Sinus leucocytosis	1	0.10	0.11	1.45	0.00	20.00
Single cell necrosis	64	6.69	6.72	21.63	0.00	100.00
Necrosis	6	0.63	0.63	3.52	0.00	20.00
Granuloma	5	0.52	0.53	4.81	0.00	60.00
Fibrosis	2	0.21	0.21	2.05	0.00	20.00
Bile duct proliferation	20	2.09	2.00	10.36	0.00	100.00
Hepatocellular hyperptrophy	5	0.52	0.42	2.69	0.00	20.00
Hepatocytic hyperplasia	2	0.21	0.21	2.05	0.00	20.00
Inflammation	1	0.10	0.11	1.45	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	946					
Anomaly	0	0.00	0.00	0.00	0.00	0.00
Hypoplasia	0	0.00	0.00	0.00	0.00	0.00
Hepatodiaphragmatic herniation	0	0.00	0.00	0.00	0.00	0.00
Congestion	0	0.00	0.00	0.00	0.00	0.00
Glycogen deposition	94	9.94	10.16	28.91	0.00	100.00
Fatty change	202	21.35	21.02	32.64	0.00	100.00
Vacuolation	78	8.25	8.34	19.97	0.00	100.00
Pigment	12	1.27	1.28	6.09	0.00	60.00
Extramedullary hemopoiesis	85	8.99	8.96	15.78	0.00	80.00
Sinusoidal dilation	1	0.11	0.11	1.46	0.00	20.00
Peribiliary mononuclear	1	0.11	0.11	1.46	0.00	20.00
Hemosiderin	3	0.32	0.32	3.26	0.00	40.00
Hepatocellular pigment	0	0.00	0.00	0.00	0.00	0.00
Inflammatory cell foci	591	62.47	61.61	36.05	0.00	120.00
Multinuclear giant cell(s)	0	0.00	0.00	0.00	0.00	0.00
Peribiliar inflammation	1	0.11	0.11	1.46	0.00	20.00
Sinus leucocytosis	0	0.00	0.00	0.00	0.00	0.00
Single cell necrosis	33	3.49	3.53	14.90	0.00	100.00
Necrosis	6	0.63	0.64	4.10	0.00	40.00
Granuloma	2	0.21	0.21	2.93	0.00	40.00
Fibrosis	2	0.21	0.21	2.06	0.00	20.00
Bile duct proliferation	25	2.64	2.22	11.84	0.00	100.00
Hepatocellular hyperptrophy	5	0.53	0.49	3.03	0.00	20.00
Hepatocytic hyperplasia	1	0.11	0.11	1.46	0.00	20.00
Inflammation	0	0.00	0.00	0.00	0.00	0.00

Tongue

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	303					
Inflammation	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	2	0.66	0.69	5.25	0.00	40.00
Atrophy, lingual gland	0	0.00	0.00	0.00	0.00	0.00
Hyperkeratosis	0	0.00	0.00	0.00	0.00	0.00
Epithelial hyperplasia	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	303					
Inflammation	2	0.66	0.43	3.28	0.00	25.00
Mononuclear cell foci	2	0.66	0.69	5.25	0.00	40.00
Atrophy, lingual gland	1	0.33	0.22	1.64	0.00	12.50
Hyperkeratosis	1	0.33	0.34	2.63	0.00	20.00
Epithelial hyperplasia	1	0.33	0.34	2.63	0.00	20.00

Esophagus

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	329					
Hyperkeratosis	3	0.91	0.97	7.62	0.00	60.00
Dilation	2	0.61	0.65	5.08	0.00	40.00
Distended with feed	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	330					
Hyperkeratosis	1	0.30	0.32	2.52	0.00	20.00
Dilation	0	0.00	0.00	0.00	0.00	0.00
Distended with feed	1	0.30	1.59	12.60	0.00	100.00

Stomach

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	936					
Intestinal metaplasia	1	0.11	0.11	1.47	0.00	20.00
Epithelial cyst	5	0.53	0.54	3.25	0.00	20.00
Mucosal cyst	3	0.32	0.32	2.53	0.00	20.00
Epithelial islets	1	0.11	0.11	1.47	0.00	20.00
Dilated glands	14	1.50	1.51	5.70	0.00	40.00
Lymphoid follicles	16	1.71	1.73	6.01	0.00	40.00
Congestion	10	1.07	1.08	5.41	0.00	40.00
Edema	6	0.64	0.65	4.62	0.00	40.00
Hyaline inclusions	139	14.85	15.26	30.75	0.00	100.00
Apoptotic bodies	1	0.11	0.11	1.47	0.00	20.00
Mineralization	2	0.21	0.22	2.07	0.00	20.00
Mononuclear cell foci	13	1.39	1.41	7.53	0.00	80.00
Inflammatory cell foci	59	6.30	6.38	18.19	0.00	100.00
Glandular stomach edema	0	0.00	0.00	0.00	0.00	0.00
Increased inflammation infiltration	6	0.64	0.65	5.07	0.00	60.00
Limiting ridge vacuolation	72	7.69	7.81	15.49	0.00	80.00
Epithelial degeneration	0	0.00	0.00	0.00	0.00	0.00
Focal spongiosis	5	0.53	0.54	7.35	0.00	100.00
Cryptabscess(es)	1	0.11	0.11	1.47	0.00	20.00
Glandular inflammation	5	0.53	0.54	6.05	0.00	80.00
Forestomach inflammation	0	0.00	0.00	0.00	0.00	0.00
Arterial inflammation	0	0.00	0.00	0.00	0.00	0.00
Erosion/ulceration	7	0.75	0.76	3.83	0.00	20.00
Necrosis	1	0.11	0.11	1.47	0.00	20.00
Inflammation	1	0.11	0.11	1.47	0.00	20.00
Hyperkeratosis	14	1.50	1.51	8.72	0.00	80.00
Parakeratosis	2	0.21	0.22	2.94	0.00	40.00
Epithelial regeneration after erosion	0	0.00	0.00	0.00	0.00	0.00
Fibrosis	1	0.11	0.11	1.47	0.00	20.00
Mucosal atrophy	1	0.11	0.11	1.47	0.00	20.00
Epithelial Hyperplasia	3	0.32	0.32	2.53	0.00	20.00
Epithelial dysplasia	1	0.11	0.11	1.47	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	916					
Intestinal metaplasia	0	0.00	0.00	0.00	0.00	0.00
Epithelial cyst	2	0.22	0.22	2.10	0.00	20.00
Mucosal cyst	0	0.00	0.00	0.00	0.00	0.00
Epithelial islets	0	0.00	0.00	0.00	0.00	0.00
Dilated glands	22	2.40	2.53	9.12	0.00	80.00
Lymphoid follicles	10	1.09	1.10	4.58	0.00	20.00
Congestion	4	0.44	0.33	2.56	0.00	20.00
Edema	4	0.44	0.44	4.69	0.00	60.00
Hyaline inclusions	118	12.88	13.25	26.69	0.00	100.00
Apoptotic bodies	0	0.00	0.00	0.00	0.00	0.00
Mineralization	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	15	1.64	1.66	7.85	0.00	60.00
Inflammatory cell foci	45	4.91	4.86	14.40	0.00	80.00
Glandular stomach edema	0	0.00	0.00	0.00	0.00	0.00
Increased inflammation infiltration	9	0.98	0.99	7.97	0.00	80.00
Limiting ridge vacuolation	56	6.11	6.32	13.66	0.00	60.00
Epithelial degeneration	1	0.11	0.11	1.49	0.00	20.00
Focal spongiosis	5	0.55	0.55	7.43	0.00	100.00
Cryptabscess(es)	1	0.11	0.11	1.49	0.00	20.00
Glandular inflammation	2	0.22	0.22	2.97	0.00	40.00
Forestomach inflammation	0	0.00	0.00	0.00	0.00	0.00
Arterial inflammation	1	0.11	0.11	1.49	0.00	20.00
Erosion/ulceration	14	1.53	1.55	5.76	0.00	40.00
Necrosis	0	0.00	0.00	0.00	0.00	0.00
Inflammation	1	0.11	0.11	1.49	0.00	20.00
Hyperkeratosis	11	1.20	1.22	7.93	0.00	80.00
Parakeratosis	1	0.11	0.11	1.49	0.00	20.00
Epithelial regeneration after erosion	1	0.11	0.11	1.49	0.00	20.00
Fibrosis	0	0.00	0.00	0.00	0.00	0.00
Mucosal atrophy	0	0.00	0.00	0.00	0.00	0.00
Epithelial Hyperplasia	1	0.11	0.11	1.49	0.00	20.00
Epithelial dysplasia	0	0.00	0.00	0.00	0.00	0.00

Forestomach

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	35					
Hyperplasia, limiting ridge	4	11.43	11.43	19.52	0.00	40.00
Hyperkeratosis	10	28.57	28.57	36.25	0.00	80.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	35					
Hyperplasia, limiting ridge	3	8.57	8.57	15.74	0.00	40.00
Hyperkeratosis	6	17.14	17.14	31.47	0.00	80.00

Glandular stomach

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	30					
Glandular dilation	0	0.00	0.00	0.00	0.00	0.00
Congestion	1	3.33	3.33	8.16	0.00	20.00
Mononuclear cell foci	1	3.33	3.33	8.16	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	35					
Glandular dilation	1	2.86	2.86	7.56	0.00	20.00
Congestion	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	0	0.00	0.00	0.00	0.00	0.00

Duodenum

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	936					
Dilation	1	0.11	0.11	1.47	0.00	20.00
Autolysis	3	0.32	0.32	4.41	0.00	60.00
Fibrosis	1	0.11	0.11	1.47	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	926					
Dilation	2	0.22	0.22	2.09	0.00	20.00
Autolysis	2	0.22	0.22	2.96	0.00	40.00
Fibrosis	0	0.00	0.00	0.00	0.00	0.00

Jejunum

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	864					
Congestion	3	0.35	1.26	10.78	0.00	100.00
Mineralization	36	4.17	4.24	14.14	0.00	100.00
Lymphoid hyperplasia	75	8.68	9.12	25.40	0.00	100.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	859					
Congestion	3	0.35	0.99	8.63	0.00	100.00
Mineralization	36	4.19	4.24	12.74	0.00	80.00
Lymphoid hyperplasia	65	7.57	7.88	23.15	0.00	100.00

Ileum

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	871					
Congestion	3	0.34	0.35	3.40	0.00	40.00
Mineralization	2	0.23	0.23	2.15	0.00	20.00
Lymphoid hyperplasia	97	11.14	11.28	29.11	0.00	100.00
Goblet cell proliferation	1	0.11	0.12	1.52	0.00	20.00
Epithelic invagination	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	860					
Congestion	0	0.00	0.00	0.00	0.00	0.00
Mineralization	3	0.35	0.35	4.59	0.00	60.00
Lymphoid hyperplasia	83	9.65	9.94	27.39	0.00	100.00
Goblet cell proliferation	0	0.00	0.00	0.00	0.00	0.00
Epithelic invagination	1	0.12	0.12	1.53	0.00	20.00

Peyer's patches NOS

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	418					
Congestion	0	0.00	0.00	0.00	0.00	0.00
Mineralization	6	1.44	1.43	6.04	0.00	40.00
Lymphoid hyperplasia	25	5.98	3.57	18.67	0.00	100.00
Germinal centres	15	3.59	3.57	18.67	0.00	100.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	418					
Congestion	3	0.72	0.71	6.55	0.00	60.00
Mineralization	16	3.83	3.81	11.81	0.00	60.00
Lymphoid hyperplasia	23	5.50	3.10	16.57	0.00	100.00
Germinal centres	13	3.11	3.10	16.28	0.00	100.00

Peyer's patches Jejunum

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	304					
Mineralization	34	11.18	11.14	16.07	0.00	60.00
Lymphoid hyperplasia	99	32.57	33.59	37.02	0.00	100.00
Hemorrhage	1	0.33	0.38	3.08	0.00	25.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	286					
Mineralization	26	9.09	9.64	16.25	0.00	60.00
Lymphoid hyperplasia	91	31.82	33.31	38.37	0.00	100.00
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00

Peyer's patches Ileum

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	323					
Mineralization	0	0.00	0.00	0.00	0.00	0.00
Lymphoid hyperplasia	165	51.08	51.89	46.74	0.00	100.00
Ileal luminal dilation	1	0.31	0.30	2.46	0.00	20.00
Hemorrhage	1	0.31	0.30	2.46	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	313					
Mineralization	0	0.00	0.00	0.00	0.00	0.00
Lymphoid hyperplasia	151	48.24	48.75	45.41	0.00	100.00
Ileal luminal dilation	0	0.00	0.00	0.00	0.00	0.00
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00

Cecum

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	931					
Cyst(s)	6	0.64	0.65	7.51	0.00	100.00
Lymphoid hyperplasia	0	0.00	0.00	0.00	0.00	0.00
Increased inflammation infiltration	1	0.11	0.11	1.47	0.00	20.00
Mononuclear cell foci	3	0.32	0.33	4.42	0.00	60.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	921					
Cyst(s)	5	0.54	0.55	7.41	0.00	100.00
Lymphoid hyperplasia	7	0.76	0.66	3.58	0.00	20.00
Increased inflammation infiltration	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	3	0.33	0.33	3.31	0.00	40.00

Colon

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	934					
Dilation	5	0.54	0.54	3.86	0.00	40.00
Nematodes	0	0.00	0.00	0.00	0.00	0.00
Inflammatory cell foci	0	0.00	0.00	0.00	0.00	0.00
Lymphoid hyperplasia	1	0.11	0.11	1.47	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	926					
Dilation	7	0.76	0.77	4.38	0.00	40.00
Nematodes	1	0.11	0.11	1.48	0.00	20.00
Inflammatory cell foci	1	0.11	0.11	1.48	0.00	20.00
Lymphoid hyperplasia	3	0.32	0.33	2.55	0.00	20.00

Rectum

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	931					
Dilation	17	1.83	1.85	6.52	0.00	40.00
Nematodes	8	0.86	0.87	5.05	0.00	40.00
Congestion	1	0.11	0.18	2.46	0.00	33.33
Mononuclear cell foci	1	0.11	0.11	1.47	0.00	20.00
Fibrosis	0	0.00	0.00	0.00	0.00	0.00
Edema	3	0.32	0.33	2.54	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	916					
Dilation	23	2.51	2.62	9.15	0.00	60.00
Nematodes	1	0.11	0.11	1.49	0.00	20.00
Congestion	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	2	0.22	0.22	2.97	0.00	40.00
Fibrosis	1	0.11	0.11	1.49	0.00	20.00
Edema	0	0.00	0.00	0.00	0.00	0.00

Salivary glands

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	323					

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	318					

Parotid salivary glands

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	85					
Ectopic salivary gland	0	0.00	0.00	0.00	0.00	0.00
Lipidosis	4	4.71	5.33	14.07	0.00	40.00
Mononuclear cell foci	4	4.71	4.42	8.22	0.00	20.00
Fatty atrophy	5	5.88	6.67	25.82	0.00	100.00
Ectopic sublingualis	0	0.00	0.00	0.00	0.00	0.00
Basophilic acini	3	3.53	1.25	4.84	0.00	18.75
Acinar hypertrophy	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	85					
Ectopic salivary gland	2	2.35	2.67	7.04	0.00	20.00
Lipidosis	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	0	0.00	0.00	0.00	0.00	0.00
Fatty atrophy	4	4.71	5.33	20.66	0.00	80.00
Ectopic sublingualis	1	1.18	0.42	1.61	0.00	6.25
Basophilic acini	3	3.53	1.25	4.84	0.00	18.75
Acinar hypertrophy	1	1.18	0.42	1.61	0.00	6.25

Submandibular salivary glands

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	335					
Inflammation	1	0.30	0.31	2.48	0.00	20.00
Mediastinal inflammation	1	0.30	0.31	2.48	0.00	20.00
Acinar hypertrophy	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	330					
Inflammation	0	0.00	0.00	0.00	0.00	0.00
Mediastinal inflammation	0	0.00	0.00	0.00	0.00	0.00
Acinar hypertrophy	4	1.21	0.39	3.13	0.00	25.00

Sublingual salivary glands

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	345					
Glandular atrophy	1	0.29	0.30	2.44	0.00	20.00
Parotid gld. ectopia	0	0.00	0.00	0.00	0.00	0.00
Atrophy	2	0.58	0.60	4.89	0.00	40.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	340					
Glandular atrophy	0	0.00	0.00	0.00	0.00	0.00
Parotid gld. ectopia	1	0.29	0.30	2.46	0.00	20.00
Atrophy	0	0.00	0.00	0.00	0.00	0.00

Urinary bladder

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	935					
Congestion	2	0.21	0.65	7.47	0.00	100.00
Mononuclear cell foci	7	0.75	0.75	4.35	0.00	40.00
Ectasia	3	0.32	0.32	2.53	0.00	20.00
Luminar blood	1	0.11	0.11	1.47	0.00	20.00
Dilation	3	0.32	0.32	3.27	0.00	40.00
Inflammation cell foci	1	0.11	0.11	1.47	0.00	20.00
Proteinaceous plug	1	0.11	0.11	1.47	0.00	20.00
Suburothelial infiltrate	1	0.11	0.11	1.47	0.00	20.00
Edema	2	0.21	0.22	2.93	0.00	40.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	926					
Congestion	1	0.11	0.11	1.48	0.00	20.00
Mononuclear cell foci	5	0.54	0.55	3.27	0.00	20.00
Ectasia	3	0.32	0.33	2.55	0.00	20.00
Luminar blood	0	0.00	0.00	0.00	0.00	0.00
Dilation	2	0.22	0.22	2.96	0.00	40.00
Inflammation cell foci	0	0.00	0.00	0.00	0.00	0.00
Proteinaceous plug	0	0.00	0.00	0.00	0.00	0.00
Suburothelial infiltrate	0	0.00	0.00	0.00	0.00	0.00
Edema	0	0.00	0.00	0.00	0.00	0.00

Urether

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	30					

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	30					

Kidneys

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	1006					
Anomaly	1	0.10	0.11	1.45	0.00	20.00
Pelvic dilation	69	6.86	6.96	14.15	0.00	60.00
Contents fluid	1	0.10	0.11	1.45	0.00	20.00
Cyst(s)	3	0.30	0.32	3.24	0.00	40.00
Tubular cysts	1	0.10	0.11	1.45	0.00	20.00
Bowman`s capsle dilation	0	0.00	0.00	0.00	0.00	0.00
Hydronephrosis	1	0.10	0.11	1.45	0.00	20.00
Congestion	0	0.00	0.00	0.00	0.00	0.00
Hemorrhage	5	0.50	0.74	7.80	0.00	100.00
Hyaline droplets	633	62.92	60.76	42.86	0.00	100.00
Lipofuscin pigment	0	0.00	0.00	0.00	0.00	0.00
Hemosiderin	0	0.00	0.00	0.00	0.00	0.00
Corticomedullary mineralization	50	4.97	4.90	13.08	0.00	80.00
Pelvic mineralization	7	0.70	0.47	2.96	0.00	20.00
Papillary mineralization	5	0.50	0.53	3.21	0.00	20.00
Mineralization	4	0.40	0.42	3.54	0.00	40.00
Tubular vacuolation	9	0.89	0.95	6.27	0.00	60.00
Tubular dilation	6	0.60	0.63	3.51	0.00	20.00
Tubular basophilia	291	28.93	29.16	26.03	0.00	100.00
Diffuse basophilia	0	0.00	0.00	0.00	0.00	0.00
Tubular degeneration	9	0.89	0.97	4.85	0.00	40.00
Tubular casts	25	2.49	2.38	7.32	0.00	40.00
Granular casts	1	0.10	0.11	1.45	0.00	20.00
Mononuclear cell foci	138	13.72	14.19	21.09	0.00	100.00
Inflammatory cell infiltration	16	1.59	1.68	9.50	0.00	80.00
Pyelitis	7	0.70	0.74	4.77	0.00	40.00
Interstitial inflammation	13	1.29	0.95	4.26	0.00	30.00
Fibrosis	6	0.60	0.63	4.07	0.00	40.00
Tubular hypertrophy	0	0.00	0.00	0.00	0.00	0.00
Urothelial hyperplasia	12	1.19	1.09	4.49	0.00	20.00
Tubular hyperplasia	1	0.10	0.11	1.45	0.00	20.00
Blastematosis	1	0.10	0.11	1.45	0.00	20.00
Nephroblastoma	2	0.20	0.14	1.52	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	996					
Anomaly	0	0.00	0.00	0.00	0.00	0.00
Pelvic dilation	49	4.92	5.00	10.04	0.00	40.00
Contents fluid	0	0.00	0.00	0.00	0.00	0.00
Cyst(s)	1	0.10	0.11	1.46	0.00	20.00
Tubular cysts	3	0.30	0.32	2.51	0.00	20.00
Bowman`s capsle dilation	1	0.10	0.11	1.46	0.00	20.00
Hydronephrosis	2	0.20	0.21	2.92	0.00	40.00
Congestion	2	0.20	0.16	1.63	0.00	20.00
Hemorrhage	3	0.30	0.46	5.07	0.00	66.67
Hyaline droplets	0	0.00	0.00	0.00	0.00	0.00
Lipofuscin pigment	9	0.90	0.96	7.82	0.00	80.00
Hemosiderin	2	0.20	0.21	2.06	0.00	20.00
Corticomedullary mineralization	493	49.50	47.23	38.73	0.00	100.00
Pelvic mineralization	7	0.70	0.59	3.13	0.00	20.00
Papillary mineralization	6	0.60	0.64	4.09	0.00	40.00
Mineralization	7	0.70	0.74	5.22	0.00	40.00
Tubular vacuolation	25	2.51	2.66	14.60	0.00	100.00
Tubular dilation	0	0.00	0.00	0.00	0.00	0.00
Tubular basophilia	252	25.30	25.16	25.62	0.00	100.00
Diffuse basophilia	4	0.40	0.43	5.83	0.00	80.00
Tubular degeneration	15	1.51	1.57	9.44	0.00	100.00
Tubular casts	21	2.11	2.23	9.33	0.00	80.00
Granular casts	3	0.30	0.32	4.38	0.00	60.00
Mononuclear cell foci	109	10.94	11.52	19.85	0.00	80.00
Inflammatory cell infiltration	6	0.60	0.64	4.58	0.00	40.00
Pyelitis	9	0.90	0.96	5.19	0.00	40.00
Interstitial inflammation	33	3.31	1.97	9.47	0.00	80.00
Fibrosis	6	0.60	0.64	4.09	0.00	40.00
Tubular hypertrophy	1	0.10	0.11	1.46	0.00	20.00
Urothelial hyperplasia	3	0.30	0.32	2.51	0.00	20.00
Tubular hyperplasia	0	0.00	0.00	0.00	0.00	0.00
Blastematosis	0	0.00	0.00	0.00	0.00	0.00
Nephroblastoma	0	0.00	0.00	0.00	0.00	0.00

Skin

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	344					
Alopecia	7	2.03	1.79	12.42	0.00	100.00
Edema	0	0.00	0.00	0.00	0.00	0.00
Inclusion cytoplasma	1	0.29	0.30	2.44	0.00	20.00
Inflammatory cell foci	1	0.29	0.30	2.44	0.00	20.00
Scab formation	0	0.00	0.00	0.00	0.00	0.00
Folliculitis	0	0.00	0.00	0.00	0.00	0.00
Epidermal necrosis	0	0.00	0.00	0.00	0.00	0.00
Abscess	1	0.29	0.30	2.44	0.00	20.00
Inflammation	0	0.00	0.00	0.00	0.00	0.00
Acanthosis	1	0.29	0.30	2.44	0.00	20.00
Parakeratosis	1	0.29	0.30	2.44	0.00	20.00
Degeneration	0	0.00	0.00	0.00	0.00	0.00
Epidermal hyperplasia	7	2.03	1.79	12.42	0.00	100.00
Paraceratosis	7	2.03	1.79	12.42	0.00	100.00
Sebaceous gland hyperplasia	7	2.03	1.79	12.42	0.00	100.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	345					
Alopecia	0	0.00	0.00	0.00	0.00	0.00
Edema	5	1.45	2.65	15.42	0.00	100.00
Inclusion cytoplasma	4	1.16	1.18	9.70	0.00	80.00
Inflammatory cell foci	0	0.00	0.00	0.00	0.00	0.00
Scab formation	1	0.29	0.29	2.43	0.00	20.00
Folliculitis	2	0.58	0.48	2.84	0.00	20.00
Epidermal necrosis	1	0.29	1.47	12.13	0.00	100.00
Abscess	0	0.00	0.00	0.00	0.00	0.00
Inflammation	5	1.45	2.54	14.10	0.00	100.00
Acanthosis	4	1.16	1.18	9.70	0.00	80.00
Parakeratosis	4	1.16	1.18	9.70	0.00	80.00
Degeneration	3	0.87	0.88	7.28	0.00	60.00
Epidermal hyperplasia	0	0.00	0.00	0.00	0.00	0.00
Paraceratosis	0	0.00	0.00	0.00	0.00	0.00
Sebaceous gland hyperplasia	0	0.00	0.00	0.00	0.00	0.00

Mammary gland

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	228					
Secretion	1	0.44	0.47	3.05	0.00	20.00
Gland. Prol., alveolar buds	1	0.44	0.47	3.05	0.00	20.00
Gland. Prol., lob. alveolar	0	0.00	0.00	0.00	0.00	0.00
Hypertrophy	2	0.88	0.93	6.10	0.00	40.00
Glandular hyperplasia	0	0.00	0.00	0.00	0.00	0.00
Lobular development	3	1.32	1.40	9.15	0.00	60.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	228					
Secretion	5	2.19	2.33	15.25	0.00	100.00
Gland. Prol., alveolar buds	3	1.32	1.40	9.15	0.00	60.00
Gland. Prol., lob. alveolar	2	0.88	0.93	6.10	0.00	40.00
Hypertrophy	0	0.00	0.00	0.00	0.00	0.00
Glandular hyperplasia	4	1.75	1.86	12.20	0.00	80.00
Lobular development	0	0.00	0.00	0.00	0.00	0.00

Testes

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	986					
Sertoli cell vacuolation	29	2.94	3.19	12.48	0.00	80.00
Tubular degeneration	39	3.96	3.67	8.91	0.00	60.00
Giant spermatids	5	0.51	0.61	6.34	0.00	80.00
Capsular fibrosis	1	0.10	0.11	1.47	0.00	20.00
Cellular debris	11	1.12	0.75	4.09	0.00	40.00
Mononuclear cell foci	0	0.00	0.00	0.00	0.00	0.00
Spermat. giant cells	3	0.30	0.32	2.53	0.00	20.00
Lymphoid cell infiltration	2	0.20	0.22	2.07	0.00	20.00
Edema	3	0.30	0.32	2.53	0.00	20.00

Epididymides

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	946					
Epithelial vacuolation	4	0.42	0.43	4.62	0.00	60.00
Oligospermia	1	0.11	0.11	1.46	0.00	20.00
Mononuclear cell foci	51	5.39	5.56	15.03	0.00	80.00
Aspermia	4	0.42	0.43	2.90	0.00	20.00
Cellular debris	2	0.21	0.21	2.06	0.00	20.00
Edema	1	0.11	0.11	1.46	0.00	20.00
Inflammation	1	0.11	0.11	1.46	0.00	20.00
Sperm granuloma	2	0.21	0.21	2.06	0.00	20.00
Atrophy	1	0.11	0.11	1.46	0.00	20.00

Seminal vesicles

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	913					
Congestion	36	3.94	6.16	20.90	0.00	100.00
Hemorrhage	2	0.22	0.22	2.07	0.00	20.00
Reduced content	1	0.11	0.11	1.47	0.00	20.00

Prostate

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	926					
Mononuclear cell foci	14	1.51	1.59	7.63	0.00	60.00
Inflammatory cell foci	8	0.86	0.87	6.55	0.00	60.00
Inflammation	28	3.02	2.96	10.61	0.00	80.00
Sperm granuloma	1	0.11	0.11	1.47	0.00	20.00
Dilatation cystic	1	0.11	0.11	1.47	0.00	20.00
Glandular atrophy	1	0.11	0.11	1.47	0.00	20.00
Diffuse hyperplasia	1	0.11	0.11	1.47	0.00	20.00
Hemosiderin	1	0.11	0.11	1.47	0.00	20.00
Hemorrhage	1	0.11	0.11	1.47	0.00	20.00

Coagulating glands

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	453					
Atrophy	0	0.00	0.00	0.00	0.00	0.00

Ovaries

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	914					
Congestion	12	1.31	2.49	13.36	0.00	100.00
Follicular cyst	1	0.11	0.11	1.47	0.00	20.00
Luteal cyst	1	0.11	0.11	1.47	0.00	20.00
Tubular dilation	6	0.66	0.65	6.22	0.00	80.00
Bursal dilation	2	0.22	0.22	2.07	0.00	20.00
Hemosiderin	1	0.11	0.11	1.47	0.00	20.00
Rete ovarii	5	0.55	0.54	3.86	0.00	40.00
Sertoli-cell tubules	1	0.11	0.11	1.47	0.00	20.00
Corpora hemorrhagicum	1	0.11	0.11	1.47	0.00	20.00
Corpora lutea	10	1.09	1.08	10.37	0.00	100.00
Interstitial cell hyperplasia	3	0.33	0.32	3.28	0.00	40.00
Fatty change	1	0.11	0.11	1.47	0.00	20.00

Oviducts

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	11					
Luminal detritus	1	9.09	6.67	11.55	0.00	20.00
Cyst	1	9.09	33.33	57.74	0.00	100.00

Uterus

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	884					
Congestion	3	0.34	0.65	7.49	0.00	100.00
Epithelial cyst(s)	1	0.11	0.11	1.47	0.00	20.00
Squamous cyst(s)	2	0.23	0.22	2.07	0.00	20.00
Endometrial cyst	17	1.92	1.84	7.72	0.00	60.00
Cornual dilation	93	10.52	13.25	24.90	0.00	100.00
Hydrometra	8	0.90	0.86	5.03	0.00	40.00
Estrus/proestrus	19	2.15	3.39	15.59	0.00	100.00
Metestrus	9	1.02	1.05	5.95	0.00	40.00
Diestrus	14	1.58	1.51	9.43	0.00	80.00
Edema, interstitial	3	0.34	0.32	2.53	0.00	20.00
Hyperplasmia endometrial stromal	2	0.23	0.22	2.94	0.00	40.00
Necrosis single cell	5	0.57	0.54	7.35	0.00	100.00

Vagina

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	918					
Luminal plug	0	0.00	0.00	0.00	0.00	0.00
Mononuclear cell foci	2	0.22	0.22	2.09	0.00	20.00
Inflammatory cell foci	1	0.11	0.11	1.48	0.00	20.00
Estrus	85	9.26	9.31	16.64	0.00	80.00
Proestrus	106	11.55	11.90	18.81	0.00	100.00
Metestrus	103	11.22	11.26	17.68	0.00	80.00
Diestrus	128	13.94	14.01	20.32	0.00	80.00
Keratisation	4	0.44	0.44	4.18	0.00	40.00
Mucification	4	0.44	0.44	3.61	0.00	40.00
Squamous cyst	1	0.11	0.11	1.48	0.00	20.00
Vacuolar degeneration	1	0.11	0.11	1.48	0.00	20.00

Bone marrow

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	830					
Fatty replacement	51	6.14	5.89	20.48	0.00	100.00
Increased myelopoiesis	7	0.84	0.94	8.38	0.00	100.00
Reduced erythropoiesis	3	0.36	0.45	3.40	0.00	33.33
Myelofibrosis	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	820					
Fatty replacement	41	5.00	4.72	16.66	0.00	100.00
Increased myelopoiesis	2	0.24	0.25	2.22	0.00	20.00
Reduced erythropoiesis	1	0.12	0.21	2.63	0.00	33.33
Myelofibrosis	1	0.12	0.12	1.58	0.00	20.00

Bone marrow - sternum

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	284					
Chondromucinous degenerenation	6	2.11	1.74	9.38	0.00	60.00
Fatty replacement	9	3.17	3.21	16.96	0.00	100.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	284					
Chondromucinous degenerenation	10	3.52	2.77	14.52	0.00	80.00
Fatty replacement	9	3.17	3.21	16.96	0.00	100.00

FemurBone marrow - femur

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	845					
Fatty replacement	84	9.94	9.94	26.74	0.00	100.00
Fatty change	1	0.12	0.12	1.54	0.00	20.00
Myelofibrosis	0	0.00	0.00	0.00	0.00	0.00
Increased erythropoeisis	1	0.12	0.12	1.54	0.00	20.00
Erythroid hyperplasia	0	0.00	0.00	0.00	0.00	0.00
Adipocytes in marrow	2	0.24	0.24	3.08	0.00	40.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	835					
Fatty replacement	64	7.66	7.66	20.80	0.00	100.00
Fatty change	0	0.00	0.00	0.00	0.00	0.00
Myelofibrosis	1	0.12	0.12	1.55	0.00	20.00
Increased erythropoeisis	0	0.00	0.00	0.00	0.00	0.00
Erythroid hyperplasia	1	0.12	0.12	1.55	0.00	20.00
Adipocytes in marrow	2	0.24	0.24	3.10	0.00	40.00

Mesenteric lymph nodes

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	927					
Congestion	3	0.32	0.76	7.64	0.00	100.00
Hemorrhage	3	0.32	0.40	3.21	0.00	33.33
Sinus dilation	5	0.54	0.54	4.87	0.00	60.00
Histiocytosis	60	6.47	6.74	23.33	0.00	100.00
Mastocytosis	14	1.51	1.59	7.33	0.00	40.00
Hemosiderin	2	0.22	0.22	2.08	0.00	20.00
Pigment deposition	2	0.22	0.22	2.08	0.00	20.00
Plasmacytosis	2	0.22	0.22	2.95	0.00	40.00
Infiltration inflammation cell	1	0.11	0.11	1.47	0.00	20.00
Lymphoid hyperplasia	363	39.16	39.66	44.06	0.00	100.00
Erythrophagocytosis	1	0.11	0.11	1.47	0.00	20.00
Lymphoid cell infiltration	1	0.11	0.11	1.47	0.00	20.00
Histiocytic aggregates	1	0.11	0.11	1.47	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	915					
Congestion	0	0.00	0.00	0.00	0.00	0.00
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00
Sinus dilation	6	0.66	0.66	6.29	0.00	80.00
Histiocytosis	64	6.99	7.25	24.39	0.00	100.00
Mastocytosis	15	1.64	1.66	9.40	0.00	80.00
Hemosiderin	0	0.00	0.00	0.00	0.00	0.00
Pigment deposition	3	0.33	0.33	4.46	0.00	60.00
Plasmacytosis	1	0.11	0.11	1.49	0.00	20.00
Infiltration inflammation cell	1	0.11	0.11	1.49	0.00	20.00
Lymphoid hyperplasia	343	37.49	38.30	43.48	0.00	100.00
Erythrophagocytosis	0	0.00	0.00	0.00	0.00	0.00
Lymphoid cell infiltration	0	0.00	0.00	0.00	0.00	0.00
Histiocytic aggregates	1	0.11	0.11	1.49	0.00	20.00

Mandibular lymph nodes

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	904					
Congestion	4	0.44	0.88	7.82	0.00	100.00
Erythrophagocytosis	1	0.11	0.11	1.48	0.00	20.00
Hemorrhage	1	0.11	0.11	1.48	0.00	20.00
Sinus dilation	2	0.22	0.22	2.09	0.00	20.00
Plasmacytosis	250	27.65	28.10	40.99	0.00	100.00
Histiocytosis	26	2.88	2.86	12.98	0.00	100.00
Mastocytosis	2	0.22	0.22	2.96	0.00	40.00
Hemosiderin	5	0.55	0.34	4.63	0.00	62.50
Lymphoid hyperplasia	339	37.50	37.93	42.82	0.00	100.00
Lymphoid atrophy	0	0.00	0.00	0.00	0.00	0.00
Lymphangiectasia	1	0.11	0.11	1.48	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	892					
Congestion	6	0.67	1.57	10.93	0.00	100.00
Erythrophagocytosis	0	0.00	0.00	0.00	0.00	0.00
Hemorrhage	4	0.45	0.45	3.65	0.00	40.00
Sinus dilation	1	0.11	0.11	1.50	0.00	20.00
Plasmacytosis	227	25.45	25.78	39.35	0.00	100.00
Histiocytosis	26	2.91	2.92	13.46	0.00	100.00
Mastocytosis	0	0.00	0.00	0.00	0.00	0.00
Hemosiderin	4	0.45	0.28	3.75	0.00	50.00
Lymphoid hyperplasia	344	38.57	38.90	42.30	0.00	100.00
Lymphoid atrophy	1	0.11	0.11	1.50	0.00	20.00
Lymphangiectasia	0	0.00	0.00	0.00	0.00	0.00

Mediastinal lymph nodes

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	56					
Congestion	2	3.57	9.23	27.83	0.00	100.00
Hemosiderin	5	8.93	13.27	28.68	0.00	100.00
Plasmacytosis	0	0.00	0.00	0.00	0.00	0.00
Lymphoid hyperplasia	10	17.86	26.54	40.28	0.00	100.00
Pigment	1	1.79	1.54	5.55	0.00	20.00
Lymhoid atrophy	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	55					
Congestion	10	18.18	19.55	32.44	0.00	100.00
Hemosiderin	22	40.00	40.15	39.92	0.00	100.00
Plasmacytosis	1	1.82	1.14	3.77	0.00	12.50
Lymphoid hyperplasia	12	21.82	20.23	25.16	0.00	80.00
Pigment	5	9.09	9.09	30.15	0.00	100.00
Lymhoid atrophy	1	1.82	1.82	6.03	0.00	20.00

Other lymph nodes

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	85					
Sinusoidal dilation	0	0.00	0.00	0.00	0.00	0.00
Congestion	2	2.35	2.86	7.26	0.00	20.00
Hemosiderin	2	2.35	1.88	5.48	0.00	20.00
Increased histiocytose	1	1.18	1.43	5.35	0.00	20.00
Lymphoid hyperplasia	18	21.18	16.65	21.15	0.00	60.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	70					
Sinusoidal dilation	0	0.00	0.00	0.00	0.00	0.00
Congestion	0	0.00	0.00	0.00	0.00	0.00
Hemosiderin	9	12.86	4.69	16.24	0.00	56.25
Increased histiocytose	0	0.00	0.00	0.00	0.00	0.00
Lymphoid hyperplasia	9	12.86	9.27	24.02	0.00	80.00

Thymus

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	917					
Cyst(s)	98	10.69	11.15	20.07	0.00	100.00
Congestion	20	2.18	2.16	7.49	0.00	60.00
Hemorrhage	32	3.49	3.49	10.31	0.00	60.00
Hemosiderin	0	0.00	0.00	0.00	0.00	0.00
Histiocytosis	15	1.64	1.62	9.98	0.00	100.00
Atrophy/ Involution	146	15.92	15.98	30.04	0.00	100.00
Lymphocytolysis/phagocytosis	7	0.76	0.76	7.90	0.00	100.00
Epithelial hyperplasia	4	0.44	0.43	2.92	0.00	20.00
Mediastinal inflammation	2	0.22	0.22	2.94	0.00	40.00
Lymphoid hyperplasia	1	0.11	0.11	1.47	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	899					
Cyst(s)	199	22.14	22.13	30.29	0.00	100.00
Congestion	15	1.67	2.08	9.26	0.00	100.00
Hemorrhage	18	2.00	2.48	10.16	0.00	100.00
Hemosiderin	1	0.11	0.11	1.48	0.00	20.00
Histiocytosis	22	2.45	2.40	13.70	0.00	100.00
Atrophy/ Involution	167	18.58	18.20	33.60	0.00	100.00
Lymphocytolysis/phagocytosis	10	1.11	1.09	10.43	0.00	100.00
Epithelial hyperplasia	13	1.45	1.42	9.15	0.00	80.00
Mediastinal inflammation	0	0.00	0.00	0.00	0.00	0.00
Lymphoid hyperplasia	0	0.00	0.00	0.00	0.00	0.00

Spleen

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	961					
Malformation	1	0.10	0.11	1.45	0.00	20.00
Erythropoiesis	19	1.98	2.00	13.73	0.00	100.00
Congestion	19	1.98	2.00	8.86	0.00	60.00
Hemopoiesis	545	56.71	57.20	42.96	0.00	100.00
Hemosiderin	238	24.77	25.05	37.20	0.00	100.00
Pigment deposits	2	0.21	0.21	2.90	0.00	40.00
Lymphoid hyperplasia	7	0.73	0.74	4.77	0.00	40.00
Megakryocytosis	2	0.21	0.21	2.90	0.00	40.00
Edema	1	0.10	0.11	1.45	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	946					
Malformation	0	0.00	0.00	0.00	0.00	0.00
Erythropoiesis	9	0.95	0.96	9.34	0.00	100.00
Congestion	26	2.75	2.83	11.96	0.00	80.00
Hemopoiesis	518	54.76	54.97	42.93	0.00	100.00
Hemosiderin	373	39.43	40.00	44.14	0.00	100.00
Pigment deposits	15	1.59	1.60	12.60	0.00	100.00
Lymphoid hyperplasia	5	0.53	0.53	3.84	0.00	40.00
Megakryocytosis	3	0.32	0.32	4.39	0.00	60.00
Edema	0	0.00	0.00	0.00	0.00	0.00

Joint

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	267					
Synovitis	3	1.12	1.03	5.83	0.00	40.00
Mononuclear cell foci	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	267					
Synovitis	1	0.37	0.39	2.80	0.00	20.00
Mononuclear cell foci	1	0.37	0.39	2.80	0.00	20.00

Bone

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	305					
Chondromucinous degeneration	9	2.95	3.16	15.02	0.00	80.00
Increased bone density	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	305					
Chondromucinous degeneration	15	4.92	5.44	20.88	0.00	100.00
Increased bone density	2	0.66	0.70	5.30	0.00	40.00

Skeletal muscle

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	333					
Myofiber degeneration	2	0.60	0.63	3.53	0.00	20.00
Mononuclear cell foci	7	2.10	2.30	7.50	0.00	40.00
Inflammatory cell foci	1	0.30	0.32	2.52	0.00	20.00
Single fiber degeneration	1	0.30	0.32	2.52	0.00	20.00
Inflammation	1	0.30	0.32	2.52	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	333					
Myofiber degeneration	2	0.60	0.52	2.95	0.00	20.00
Mononuclear cell foci	5	1.50	1.59	6.53	0.00	40.00
Inflammatory cell foci	0	0.00	0.00	0.00	0.00	0.00
Single fiber degeneration	1	0.30	0.32	2.52	0.00	20.00
Inflammation	0	0.00	0.00	0.00	0.00	0.00

Body cavities

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	3					
Cystic structure	0	0.00	0.00	0.00	0.00	0.00
Mineralization	1	33.33	33.33	57.74	0.00	100.00
Fat necrosis	2	66.67	66.67	57.74	0.00	100.00
Skelet muscle infiltration	2	66.67	66.67	57.74	0.00	100.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	0					
Cystic structure	0	0.00	0.00	0.00	0.00	0.00
Mineralization	0	0.00	0.00	0.00	0.00	0.00
Fat necrosis	0	0.00	0.00	0.00	0.00	0.00
Skelet muscle infiltration	0	0.00	0.00	0.00	0.00	0.00

Adipose tissue

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	6					

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	6					

Injection sides

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	25					
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00
Degeneration	0	0.00	0.00	0.00	0.00	0.00
Inflammation	6	24.00	24.00	43.36	0.00	100.00
Phlebitis	4	16.00	16.00	35.78	0.00	80.00
Periphlebitis	3	12.00	12.00	26.83	0.00	60.00
Perivascular fibrosis	0	0.00	0.00	0.00	0.00	0.00
Thrombosis	1	4.00	4.00	8.94	0.00	20.00
Intimal poliferation	5	20.00	20.00	28.28	0.00	60.00
Medial degeneration	0	0.00	0.00	0.00	0.00	0.00
Fibrosis	2	8.00	8.00	10.95	0.00	20.00
Perifolliculitis	1	4.00	4.00	8.94	0.00	20.00
Scab formation	3	12.00	12.00	26.83	0.00	60.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	20					
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00
Degeneration	0	0.00	0.00	0.00	0.00	0.00
Inflammation	7	35.00	35.00	34.16	0.00	80.00
Phlebitis	0	0.00	0.00	0.00	0.00	0.00
Periphlebitis	0	0.00	0.00	0.00	0.00	0.00
Perivascular fibrosis	0	0.00	0.00	0.00	0.00	0.00
Thrombosis	1	5.00	5.00	10.00	0.00	20.00
Intimal poliferation	3	15.00	15.00	19.15	0.00	40.00
Medial degeneration	0	0.00	0.00	0.00	0.00	0.00
Fibrosis	0	0.00	0.00	0.00	0.00	0.00
Perifolliculitis	0	0.00	0.00	0.00	0.00	0.00
Scab formation	0	0.00	0.00	0.00	0.00	0.00

Injection sides- right

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	5					
Subcutan fibrosis	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	5					
Subcutan fibrosis	1	20.00	20.00	0.00	20.00	20.00

Injection sides- left

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	5					
Inflammatory cell infiltration	2	40.00	40.00	0.00	40.00	40.00
Subcutan fibrosis	1	20.00	20.00	0.00	20.00	20.00
Dermal inflammation	1	20.00	20.00	0.00	20.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	5					
Inflammatory cell infiltration	0	0.00	0.00	0.00	0.00	0.00
Subcutan fibrosis	4	80.00	80.00	0.00	80.00	80.00
Dermal inflammation	0	0.00	0.00	0.00	0.00	0.00

Injection site: tail

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	20					
Hemorrhage	0	0.00	0.00	0.00	0.00	0.00
Inflammatory cell infiltration	0	0.00	0.00	0.00	0.00	0.00
Inflammation	2	10.00	6.67	11.55	0.00	20.00
Thrombosis	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	20					
Hemorrhage	1	5.00	3.33	5.77	0.00	10.00
Inflammatory cell infiltration	1	5.00	3.33	5.77	0.00	10.00
Inflammation	0	0.00	0.00	0.00	0.00	0.00
Thrombosis	2	10.00	0.00	0.00	0.00	0.00

Retroorbital tissue

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	10					
Hemorrhage	6	60.00	60.00	0.00	60.00	60.00
Inflammation	2	10.00	20.00	28.28	0.00	40.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	10					
Hemorrhage	7	70.00	70.00	14.14	60.00	80.00
Inflammation	4	40.00	40.00	0.00	40.00	40.00

Treated skin

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	20					
Inflammation	2	10.00	13.33	11.55	0.00	20.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	20					
Inflammation	0	0.00	0.00	0.00	0.00	0.00

Untreated skin

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	10					
Mixed cell infiltration	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	10					
Mixed cell infiltration	2	20.00	20.00	0.00	20.00	20.00

Ears

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	5					

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	5					

Tail

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	5					
Intimal thickening	0	0.00	0.00	0.00	0.00	0.00
Osteonecrosis	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	5					
Intimal thickening	1	20.00	20.00	0.00	20.00	20.00
Osteonecrosis	1	20.00	20.00	0.00	20.00	20.00

Infusion site

Male	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	12					
Necrosis	8	66.67	66.67	0.00	66.67	66.67
Vascular fibrosis	3	25.00	25.00	0.00	25.00	25.00
Periphlebitis	8	66.67	66.67	0.00	66.67	66.67
Thrombophlebitis	0	0.00	0.00	0.00	0.00	0.00
Inflammation	0	0.00	0.00	0.00	0.00	0.00

Female	Total n	Total %	Mean %	STDEV %	MIN %	MAX %
Numbers of rats examined	0					
Necrosis	0	0.00	0.00	0.00	0.00	0.00
Vascular fibrosis	0	0.00	0.00	0.00	0.00	0.00
Periphlebitis	0	0.00	0.00	0.00	0.00	0.00
Thrombophlebitis	0	0.00	0.00	0.00	0.00	0.00
Inflammation	0	0.00	0.00	0.00	0.00	0.00